1
|
Warreman EB, Nooteboom LA, Terry MB, Hoek HW, Leenen PJM, van Rossum EFC, Ramlal D, Vermeiren RRJM, Ester WA. Psychological, behavioural and biological factors associated with gastrointestinal symptoms in autistic adults and adults with autistic traits. Autism 2023; 27:2173-2186. [PMID: 36794469 PMCID: PMC10504819 DOI: 10.1177/13623613231155324] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/17/2023]
Abstract
LAY ABSTRACT Little is known about factors related to the increased risk for gastrointestinal symptoms in adults with an autism spectrum disorder (ASD), while the negative impact of gastrointestinal symptoms is evident. Especially, the relationship between gastrointestinal symptoms and psychological, behavioural, and biological risk factors in adults with ASD (traits) is unclear. Autistic peer support workers and autism-advocates also emphasised the importance of identifying risk factors, because of the high prevalence of gastrointestinal problems in people with ASD. Therefore, our study investigated which psychological, behavioural, and biological factors are associated with gastrointestinal symptoms in adults with ASD or with autistic traits. We analysed data from 31,185 adults in the Dutch Lifelines Study. Questionnaires were used to evaluate the presence of an autism spectrum disorder diagnosis, autistic traits, gastrointestinal symptoms, psychological and behavioural factors. Biological factors were examined with body measurements. We found that not only adults with ASD but also adults with higher levels of autistic traits were at increased risk for gastrointestinal symptoms. Adults with ASD who experienced psychological problems (psychiatric problems, worse perceived health, chronic stress) had a higher risk for gastrointestinal symptoms than adults with ASD without these psychological problems. Moreover, adults with higher levels of autistic traits were less physically active, which was also associated with gastrointestinal symptoms. In conclusion, our study highlights the relevance of identifying psychological problems and evaluating physical activity when trying to help adults with ASD or autistic traits and gastrointestinal symptoms. This suggests that healthcare professionals should be more aware of behavioural and psychological risk factors when evaluating gastrointestinal symptoms in adults with ASD (traits).
Collapse
Affiliation(s)
- EB Warreman
- Leiden University Medical Center, The Netherlands
| | - LA Nooteboom
- Leiden University Medical Center, The Netherlands
| | | | - HW Hoek
- Columbia University, USA
- University Medical Center Groningen, The Netherlands
- Parnassia Group, The Netherlands
| | - PJM Leenen
- Erasmus University Medical Center, The Netherlands
| | | | - D Ramlal
- Parnassia Group, The Netherlands
| | - RRJM Vermeiren
- Leiden University Medical Center, The Netherlands
- Parnassia Group, The Netherlands
| | - WA Ester
- Leiden University Medical Center, The Netherlands
- Parnassia Group, The Netherlands
| |
Collapse
|
2
|
Smitherman EA, Chahine RA, Beukelman T, Lewandowski LB, Rahman AKMF, Wenderfer SE, Curtis JR, Hersh AO, Abulaban K, Adams A, Adams M, Agbayani R, Aiello J, Akoghlanian S, Alejandro C, Allenspach E, Alperin R, Alpizar M, Amarilyo G, Ambler W, Anderson E, Ardoin S, Armendariz S, Baker E, Balboni I, Balevic S, Ballenger L, Ballinger S, Balmuri N, Barbar‐Smiley F, Barillas‐Arias L, Basiaga M, Baszis K, Becker M, Bell‐Brunson H, Beltz E, Benham H, Benseler S, Bernal W, Beukelman T, Bigley T, Binstadt B, Black C, Blakley M, Bohnsack J, Boland J, Boneparth A, Bowman S, Bracaglia C, Brooks E, Brothers M, Brown A, Brunner H, Buckley M, Buckley M, Bukulmez H, Bullock D, Cameron B, Canna S, Cannon L, Carper P, Cartwright V, Cassidy E, Cerracchio L, Chalom E, Chang J, Chang‐Hoftman A, Chauhan V, Chira P, Chinn T, Chundru K, Clairman H, Co D, Confair A, Conlon H, Connor R, Cooper A, Cooper J, Cooper S, Correll C, Corvalan R, Costanzo D, Cron R, Curiel‐Duran L, Curington T, Curry M, Dalrymple A, Davis A, Davis C, Davis C, Davis T, De Benedetti F, De Ranieri D, Dean J, Dedeoglu F, DeGuzman M, Delnay N, Dempsey V, DeSantis E, Dickson T, Dingle J, Donaldson B, Dorsey E, Dover S, Dowling J, Drew J, Driest K, Du Q, Duarte K, Durkee D, Duverger E, Dvergsten J, Eberhard A, Eckert M, Ede K, Edelheit B, Edens C, Edens C, Edgerly Y, Elder M, Ervin B, Fadrhonc S, Failing C, Fair D, Falcon M, Favier L, Federici S, Feldman B, Fennell J, Ferguson I, Ferguson P, Ferreira B, Ferrucho R, Fields K, Finkel T, Fitzgerald M, Fleming C, Flynn O, Fogel L, Fox E, Fox M, Franco L, Freeman M, Fritz K, Froese S, Fuhlbrigge R, Fuller J, George N, Gerhold K, Gerstbacher D, Gilbert M, Gillispie‐Taylor M, Giverc E, Godiwala C, Goh I, Goheer H, Goldsmith D, Gotschlich E, Gotte A, Gottlieb B, Gracia C, Graham T, Grevich S, Griffin T, Griswold J, Grom A, Guevara M, Guittar P, Guzman M, Hager M, Hahn T, Halyabar O, Hammelev E, Hance M, Hanson A, Harel L, Haro S, Harris J, Harry O, Hartigan E, Hausmann J, Hay A, Hayward K, Heiart J, Hekl K, Henderson L, Henrickson M, Hersh A, Hickey K, Hill P, Hillyer S, Hiraki L, Hiskey M, Hobday P, Hoffart C, Holland M, Hollander M, Hong S, Horwitz M, Hsu J, Huber A, Huggins J, Hui‐Yuen J, Hung C, Huntington J, Huttenlocher A, Ibarra M, Imundo L, Inman C, Insalaco A, Jackson A, Jackson S, James K, Janow G, Jaquith J, Jared S, Johnson N, Jones J, Jones J, Jones J, Jones K, Jones S, Joshi S, Jung L, Justice C, Justiniano A, Karan N, Kaufman K, Kemp A, Kessler E, Khalsa U, Kienzle B, Kim S, Kimura Y, Kingsbury D, Kitcharoensakkul M, Klausmeier T, Klein K, Klein‐Gitelman M, Kompelien B, Kosikowski A, Kovalick L, Kracker J, Kramer S, Kremer C, Lai J, Lam J, Lang B, Lapidus S, Lapin B, Lasky A, Latham D, Lawson E, Laxer R, Lee P, Lee P, Lee T, Lentini L, Lerman M, Levy D, Li S, Lieberman S, Lim L, Lin C, Ling N, Lingis M, Lo M, Lovell D, Lowman D, Luca N, Lvovich S, Madison C, Madison J, Manzoni SM, Malla B, Maller J, Malloy M, Mannion M, Manos C, Marques L, Martyniuk A, Mason T, Mathus S, McAllister L, McCarthy K, McConnell K, McCormick E, McCurdy D, Stokes PM, McGuire S, McHale I, McMonagle A, McMullen‐Jackson C, Meidan E, Mellins E, Mendoza E, Mercado R, Merritt A, Michalowski L, Miettunen P, Miller M, Milojevic D, Mirizio E, Misajon E, Mitchell M, Modica R, Mohan S, Moore K, Moorthy L, Morgan S, Dewitt EM, Moss C, Moussa T, Mruk V, Murphy A, Muscal E, Nadler R, Nahal B, Nanda K, Nasah N, Nassi L, Nativ S, Natter M, Neely J, Nelson B, Newhall L, Ng L, Nicholas J, Nicolai R, Nigrovic P, Nocton J, Nolan B, Oberle E, Obispo B, O'Brien B, O'Brien T, Okeke O, Oliver M, Olson J, O'Neil K, Onel K, Orandi A, Orlando M, Osei‐Onomah S, Oz R, Pagano E, Paller A, Pan N, Panupattanapong S, Pardeo M, Paredes J, Parsons A, Patel J, Pentakota K, Pepmueller P, Pfeiffer T, Phillippi K, Marafon DP, Phillippi K, Ponder L, Pooni R, Prahalad S, Pratt S, Protopapas S, Puplava B, Quach J, Quinlan‐Waters M, Rabinovich C, Radhakrishna S, Rafko J, Raisian J, Rakestraw A, Ramirez C, Ramsay E, Ramsey S, Randell R, Reed A, Reed A, Reed A, Reid H, Remmel K, Repp A, Reyes A, Richmond A, Riebschleger M, Ringold S, Riordan M, Riskalla M, Ritter M, Rivas‐Chacon R, Robinson A, Rodela E, Rodriquez M, Rojas K, Ronis T, Rosenkranz M, Rosolowski B, Rothermel H, Rothman D, Roth‐Wojcicki E, Rouster – Stevens K, Rubinstein T, Ruth N, Saad N, Sabbagh S, Sacco E, Sadun R, Sandborg C, Sanni A, Santiago L, Sarkissian A, Savani S, Scalzi L, Schanberg L, Scharnhorst S, Schikler K, Schlefman A, Schmeling H, Schmidt K, Schmitt E, Schneider R, Schollaert‐Fitch K, Schulert G, Seay T, Seper C, Shalen J, Sheets R, Shelly A, Shenoi S, Shergill K, Shirley J, Shishov M, Shivers C, Silverman E, Singer N, Sivaraman V, Sletten J, Smith A, Smith C, Smith J, Smith J, Smitherman E, Soep J, Son M, Spence S, Spiegel L, Spitznagle J, Sran R, Srinivasalu H, Stapp H, Steigerwald K, Rakovchik YS, Stern S, Stevens A, Stevens B, Stevenson R, Stewart K, Stingl C, Stokes J, Stoll M, Stringer E, Sule S, Sumner J, Sundel R, Sutter M, Syed R, Syverson G, Szymanski A, Taber S, Tal R, Tambralli A, Taneja A, Tanner T, Tapani S, Tarshish G, Tarvin S, Tate L, Taxter A, Taylor J, Terry M, Tesher M, Thatayatikom A, Thomas B, Tiffany K, Ting T, Tipp A, Toib D, Torok K, Toruner C, Tory H, Toth M, Tse S, Tubwell V, Twilt M, Uriguen S, Valcarcel T, Van Mater H, Vannoy L, Varghese C, Vasquez N, Vazzana K, Vehe R, Veiga K, Velez J, Verbsky J, Vilar G, Volpe N, von Scheven E, Vora S, Wagner J, Wagner‐Weiner L, Wahezi D, Waite H, Walker J, Walters H, Muskardin TW, Waqar L, Waterfield M, Watson M, Watts A, Weiser P, Weiss J, Weiss P, Wershba E, White A, Williams C, Wise A, Woo J, Woolnough L, Wright T, Wu E, Yalcindag A, Yee M, Yen E, Yeung R, Yomogida K, Yu Q, Zapata R, Zartoshti A, Zeft A, Zeft R, Zhang Y, Zhao Y, Zhu A, Zic C. Childhood-Onset Lupus Nephritis in the Childhood Arthritis and Rheumatology Research Alliance Registry: Short-Term Kidney Status and Variation in Care. Arthritis Care Res (Hoboken) 2023; 75:1553-1562. [PMID: 36775844 PMCID: PMC10500561 DOI: 10.1002/acr.25002] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/23/2021] [Revised: 07/14/2022] [Accepted: 08/16/2022] [Indexed: 11/10/2022]
Abstract
OBJECTIVE The goal was to characterize short-term kidney status and describe variation in early care utilization in a multicenter cohort of patients with childhood-onset systemic lupus erythematosus (cSLE) and nephritis. METHODS We analyzed previously collected prospective data from North American patients with cSLE with kidney biopsy-proven nephritis enrolled in the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry from March 2017 through December 2019. We determined the proportion of patients with abnormal kidney status at the most recent registry visit and applied generalized linear mixed models to identify associated factors. We also calculated frequency of medication use, both during induction and ever recorded. RESULTS We identified 222 patients with kidney biopsy-proven nephritis, with 64% class III/IV nephritis on initial biopsy. At the most recent registry visit at median (interquartile range) of 17 (8-29) months from initial kidney biopsy, 58 of 106 patients (55%) with available data had abnormal kidney status. This finding was associated with male sex (odds ratio [OR] 3.88, 95% confidence interval [95% CI] 1.21-12.46) and age at cSLE diagnosis (OR 1.23, 95% CI 1.01-1.49). Patients with class IV nephritis were more likely than class III to receive cyclophosphamide and rituximab during induction. There was substantial variation in mycophenolate, cyclophosphamide, and rituximab ever use patterns across rheumatology centers. CONCLUSION In this cohort with predominately class III/IV nephritis, male sex and older age at cSLE diagnosis were associated with abnormal short-term kidney status. We also observed substantial variation in contemporary medication use for pediatric lupus nephritis between pediatric rheumatology centers. Additional studies are needed to better understand the impact of this variation on long-term kidney outcomes.
Collapse
|
3
|
Hahn T, Daymont C, Beukelman T, Groh B, Hays K, Bingham CA, Scalzi L, Abel N, Abulaban K, Adams A, Adams M, Agbayani R, Aiello J, Akoghlanian S, Alejandro C, Allenspach E, Alperin R, Alpizar M, Amarilyo G, Ambler W, Anderson E, Ardoin S, Armendariz S, Baker E, Balboni I, Balevic S, Ballenger L, Ballinger S, Balmuri N, Barbar-Smiley F, Barillas-Arias L, Basiaga M, Baszis K, Becker M, Bell-Brunson H, Beltz E, Benham H, Benseler S, Bernal W, Beukelman T, Bigley T, Binstadt B, Black C, Blakley M, Bohnsack J, Boland J, Boneparth A, Bowman S, Bracaglia C, Brooks E, Brothers M, Brown A, Brunner H, Buckley M, Buckley M, Bukulmez H, Bullock D, Cameron B, Canna S, Cannon L, Carper P, Cartwright V, Cassidy E, Cerracchio L, Chalom E, Chang J, Chang-Hoftman A, Chauhan V, Chira P, Chinn T, Chundru K, Clairman H, Co D, Confair A, Conlon H, Connor R, Cooper A, Cooper J, Cooper S, Correll C, Corvalan R, Costanzo D, Cron R, Curiel-Duran L, Curington T, Curry M, Dalrymple A, Davis A, Davis C, Davis C, Davis T, De Benedetti F, De Ranieri D, Dean J, Dedeoglu F, DeGuzman M, Delnay N, Dempsey V, DeSantis E, Dickson T, Dingle J, Donaldson B, Dorsey E, Dover S, Dowling J, Drew J, Driest K, Du Q, Duarte K, Durkee D, Duverger E, Dvergsten J, Eberhard A, Eckert M, Ede K, Edelheit B, Edens C, Edens C, Edgerly Y, Elder M, Ervin B, Fadrhonc S, Failing C, Fair D, Falcon M, Favier L, Federici S, Feldman B, Fennell J, Ferguson I, Ferguson P, Ferreira B, Ferrucho R, Fields K, Finkel T, Fitzgerald M, Fleming C, Flynn O, Fogel L, Fox E, Fox M, Franco L, Freeman M, Fritz K, Froese S, Fuhlbrigge R, Fuller J, George N, Gerhold K, Gerstbacher D, Gilbert M, Gillispie-Taylor M, Giverc E, Godiwala C, Goh I, Goheer H, Goldsmith D, Gotschlich E, Gotte A, Gottlieb B, Gracia C, Graham T, Grevich S, Griffin T, Griswold J, Grom A, Guevara M, Guittar P, Guzman M, Hager M, Hahn T, Halyabar O, Hammelev E, Hance M, Hanson A, Harel L, Haro S, Harris J, Harry O, Hartigan E, Hausmann J, Hay A, Hayward K, Heiart J, Hekl K, Henderson L, Henrickson M, Hersh A, Hickey K, Hill P, Hillyer S, Hiraki L, Hiskey M, Hobday P, Hoffart C, Holland M, Hollander M, Hong S, Horwitz M, Hsu J, Huber A, Huggins J, Hui-Yuen J, Hung C, Huntington J, Huttenlocher A, Ibarra M, Imundo L, Inman C, Insalaco A, Jackson A, Jackson S, James K, Janow G, Jaquith J, Jared S, Johnson N, Jones J, Jones J, Jones J, Jones K, Jones S, Joshi S, Jung L, Justice C, Justiniano A, Karan N, Kaufman K, Kemp A, Kessler E, Khalsa U, Kienzle B, Kim S, Kimura Y, Kingsbury D, Kitcharoensakkul M, Klausmeier T, Klein K, Klein-Gitelman M, Kompelien B, Kosikowski A, Kovalick L, Kracker J, Kramer S, Kremer C, Lai J, Lam J, Lang B, Lapidus S, Lapin B, Lasky A, Latham D, Lawson E, Laxer R, Lee P, Lee P, Lee T, Lentini L, Lerman M, Levy D, Li S, Lieberman S, Lim L, Lin C, Ling N, Lingis M, Lo M, Lovell D, Lowman D, Luca N, Lvovich S, Madison C, Madison J, Manzoni SM, Malla B, Maller J, Malloy M, Mannion M, Manos C, Marques L, Martyniuk A, Mason T, Mathus S, McAllister L, McCarthy K, McConnell K, McCormick E, McCurdy D, Stokes PMC, McGuire S, McHale I, McMonagle A, McMullen-Jackson C, Meidan E, Mellins E, Mendoza E, Mercado R, Merritt A, Michalowski L, Miettunen P, Miller M, Milojevic D, Mirizio E, Misajon E, Mitchell M, Modica R, Mohan S, Moore K, Moorthy L, Morgan S, Dewitt EM, Moss C, Moussa T, Mruk V, Murphy A, Muscal E, Nadler R, Nahal B, Nanda K, Nasah N, Nassi L, Nativ S, Natter M, Neely J, Nelson B, Newhall L, Ng L, Nicholas J, Nicolai R, Nigrovic P, Nocton J, Nolan B, Oberle E, Obispo B, O’Brien B, O’Brien T, Okeke O, Oliver M, Olson J, O’Neil K, Onel K, Orandi A, Orlando M, Osei-Onomah S, Oz R, Pagano E, Paller A, Pan N, Panupattanapong S, Pardeo M, Paredes J, Parsons A, Patel J, Pentakota K, Pepmueller P, Pfeiffer T, Phillippi K, Marafon DP, Phillippi K, Ponder L, Pooni R, Prahalad S, Pratt S, Protopapas S, Puplava B, Quach J, Quinlan-Waters M, Rabinovich C, Radhakrishna S, Rafko J, Raisian J, Rakestraw A, Ramirez C, Ramsay E, Ramsey S, Randell R, Reed A, Reed A, Reed A, Reid H, Remmel K, Repp A, Reyes A, Richmond A, Riebschleger M, Ringold S, Riordan M, Riskalla M, Ritter M, Rivas-Chacon R, Robinson A, Rodela E, Rodriquez M, Rojas K, Ronis T, Rosenkranz M, Rosolowski B, Rothermel H, Rothman D, Roth-Wojcicki E, Rouster-Stevens K, Rubinstein T, Ruth N, Saad N, Sabbagh S, Sacco E, Sadun R, Sandborg C, Sanni A, Santiago L, Sarkissian A, Savani S, Scalzi L, Schanberg L, Scharnhorst S, Schikler K, Schlefman A, Schmeling H, Schmidt K, Schmitt E, Schneider R, Schollaert-Fitch K, Schulert G, Seay T, Seper C, Shalen J, Sheets R, Shelly A, Shenoi S, Shergill K, Shirley J, Shishov M, Shivers C, Silverman E, Singer N, Sivaraman V, Sletten J, Smith A, Smith C, Smith J, Smith J, Smitherman E, Soep J, Son M, Spence S, Spiegel L, Spitznagle J, Sran R, Srinivasalu H, Stapp H, Steigerwald K, Rakovchik YS, Stern S, Stevens A, Stevens B, Stevenson R, Stewart K, Stingl C, Stokes J, Stoll M, Stringer E, Sule S, Sumner J, Sundel R, Sutter M, Syed R, Syverson G, Szymanski A, Taber S, Tal R, Tambralli A, Taneja A, Tanner T, Tapani S, Tarshish G, Tarvin S, Tate L, Taxter A, Taylor J, Terry M, Tesher M, Thatayatikom A, Thomas B, Tiffany K, Ting T, Tipp A, Toib D, Torok K, Toruner C, Tory H, Toth M, Tse S, Tubwell V, Twilt M, Uriguen S, Valcarcel T, Van Mater H, Vannoy L, Varghese C, Vasquez N, Vazzana K, Vehe R, Veiga K, Velez J, Verbsky J, Vilar G, Volpe N, von Scheven E, Vora S, Wagner J, Wagner-Weiner L, Wahezi D, Waite H, Walker J, Walters H, Muskardin TW, Waqar L, Waterfield M, Watson M, Watts A, Weiser P, Weiss J, Weiss P, Wershba E, White A, Williams C, Wise A, Woo J, Woolnough L, Wright T, Wu E, Yalcindag A, Yee M, Yen E, Yeung R, Yomogida K, Yu Q, Zapata R, Zartoshti A, Zeft A, Zeft R, Zhang Y, Zhao Y, Zhu A, Zic C. Intraarticular steroids as DMARD-sparing agents for juvenile idiopathic arthritis flares: Analysis of the Childhood Arthritis and Rheumatology Research Alliance Registry. Pediatr Rheumatol Online J 2022; 20:107. [PMID: 36434731 PMCID: PMC9701017 DOI: 10.1186/s12969-022-00770-y] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/13/2022] [Accepted: 11/08/2022] [Indexed: 11/26/2022] Open
Abstract
BACKGROUND Children with juvenile idiopathic arthritis (JIA) who achieve a drug free remission often experience a flare of their disease requiring either intraarticular steroids (IAS) or systemic treatment with disease modifying anti-rheumatic drugs (DMARDs). IAS offer an opportunity to recapture disease control and avoid exposure to side effects from systemic immunosuppression. We examined a cohort of patients treated with IAS after drug free remission and report the probability of restarting systemic treatment within 12 months. METHODS We analyzed a cohort of patients from the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry who received IAS for a flare after a period of drug free remission. Historical factors and clinical characteristics and of the patients including data obtained at the time of treatment were analyzed. RESULTS We identified 46 patients who met the inclusion criteria. Of those with follow up data available 49% had restarted systemic treatment 6 months after IAS injection and 70% had restarted systemic treatment at 12 months. The proportion of patients with prior use of a biologic DMARD was the only factor that differed between patients who restarted systemic treatment those who did not, both at 6 months (79% vs 35%, p < 0.01) and 12 months (81% vs 33%, p < 0.05). CONCLUSION While IAS are an option for all patients who flare after drug free remission, it may not prevent the need to restart systemic treatment. Prior use of a biologic DMARD may predict lack of success for IAS. Those who previously received methotrexate only, on the other hand, are excellent candidates for IAS.
Collapse
Affiliation(s)
- Timothy Hahn
- Department of Pediatrics, Penn State Children's Hospital, 500 University Dr, Hershey, 90 Hope Drive, P.O. Box 855, Hershey, PA, 17033-0855, USA.
| | - Carrie Daymont
- grid.240473.60000 0004 0543 9901Department of Pediatrics, Penn State Children’s Hospital, 500 University Dr, Hershey, 90 Hope Drive, P.O. Box 855, Hershey, PA 17033-0855 USA
| | - Timothy Beukelman
- grid.265892.20000000106344187Department of Pediatrics, University of Alabama at Birmingham, CPPN G10, 1600 7th Ave South, Birmingham, AL 35233 USA
| | - Brandt Groh
- grid.240473.60000 0004 0543 9901Department of Pediatrics, Penn State Children’s Hospital, 500 University Dr, Hershey, 90 Hope Drive, P.O. Box 855, Hershey, PA 17033-0855 USA
| | | | - Catherine April Bingham
- grid.240473.60000 0004 0543 9901Department of Pediatrics, Penn State Children’s Hospital, 500 University Dr, Hershey, 90 Hope Drive, P.O. Box 855, Hershey, PA 17033-0855 USA
| | - Lisabeth Scalzi
- grid.240473.60000 0004 0543 9901Department of Pediatrics, Penn State Children’s Hospital, 500 University Dr, Hershey, 90 Hope Drive, P.O. Box 855, Hershey, PA 17033-0855 USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
4
|
Terry M, Keith J, Oden A, Birket S. 387 Preinfection knockdown of Muc5b reduces severity of chronic Pseudomonas aeruginosa infection in the cystic fibrosis transmembrane conductance regulator knockout rat. J Cyst Fibros 2022. [PMCID: PMC9527891 DOI: 10.1016/s1569-1993(22)01077-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
|
5
|
Soulsby WD, Balmuri N, Cooley V, Gerber LM, Lawson E, Goodman S, Onel K, Mehta B, Abel N, Abulaban K, Adams A, Adams M, Agbayani R, Aiello J, Akoghlanian S, Alejandro C, Allenspach E, Alperin R, Alpizar M, Amarilyo G, Ambler W, Anderson E, Ardoin S, Armendariz S, Baker E, Balboni I, Balevic S, Ballenger L, Ballinger S, Balmuri N, Barbar-Smiley F, Barillas-Arias L, Basiaga M, Baszis K, Becker M, Bell-Brunson H, Beltz E, Benham H, Benseler S, Bernal W, Beukelman T, Bigley T, Binstadt B, Black C, Blakley M, Bohnsack J, Boland J, Boneparth A, Bowman S, Bracaglia C, Brooks E, Brothers M, Brown A, Brunner H, Buckley M, Buckley M, Bukulmez H, Bullock D, Cameron B, Canna S, Cannon L, Carper P, Cartwright V, Cassidy E, Cerracchio L, Chalom E, Chang J, Chang-Hoftman A, Chauhan V, Chira P, Chinn T, Chundru K, Clairman H, Co D, Confair A, Conlon H, Connor R, Cooper A, Cooper J, Cooper S, Correll C, Corvalan R, Costanzo D, Cron R, Curiel-Duran L, Curington T, Curry M, Dalrymple A, Davis A, Davis C, Davis C, Davis T, De Benedetti F, De Ranieri D, Dean J, Dedeoglu F, DeGuzman M, Delnay N, Dempsey V, DeSantis E, Dickson T, Dingle J, Donaldson B, Dorsey E, Dover S, Dowling J, Drew J, Driest K, Du Q, Duarte K, Durkee D, Duverger E, Dvergsten J, Eberhard A, Eckert M, Ede K, Edelheit B, Edens C, Edens C, Edgerly Y, Elder M, Ervin B, Fadrhonc S, Failing C, Fair D, Falcon M, Favier L, Federici S, Feldman B, Fennell J, Ferguson I, Ferguson P, Ferreira B, Ferrucho R, Fields K, Finkel T, Fitzgerald M, Fleming C, Flynn O, Fogel L, Fox E, Fox M, Franco L, Freeman M, Fritz K, Froese S, Fuhlbrigge R, Fuller J, George N, Gerhold K, Gerstbacher D, Gilbert M, Gillispie-Taylor M, Giverc E, Godiwala C, Goh I, Goheer H, Goldsmith D, Gotschlich E, Gotte A, Gottlieb B, Gracia C, Graham T, Grevich S, Griffin T, Griswold J, Grom A, Guevara M, Guittar P, Guzman M, Hager M, Hahn T, Halyabar O, Hammelev E, Hance M, Hanson A, Harel L, Haro S, Harris J, Harry O, Hartigan E, Hausmann J, Hay A, Hayward K, Heiart J, Hekl K, Henderson L, Henrickson M, Hersh A, Hickey K, Hill P, Hillyer S, Hiraki L, Hiskey M, Hobday P, Hoffart C, Holland M, Hollander M, Hong S, Horwitz M, Hsu J, Huber A, Huggins J, Hui-Yuen J, Hung C, Huntington J, Huttenlocher A, Ibarra M, Imundo L, Inman C, Insalaco A, Jackson A, Jackson S, James K, Janow G, Jaquith J, Jared S, Johnson N, Jones J, Jones J, Jones J, Jones K, Jones S, Joshi S, Jung L, Justice C, Justiniano A, Karan N, Kaufman K, Kemp A, Kessler E, Khalsa U, Kienzle B, Kim S, Kimura Y, Kingsbury D, Kitcharoensakkul M, Klausmeier T, Klein K, Klein-Gitelman M, Kompelien B, Kosikowski A, Kovalick L, Kracker J, Kramer S, Kremer C, Lai J, Lam J, Lang B, Lapidus S, Lapin B, Lasky A, Latham D, Lawson E, Laxer R, Lee P, Lee P, Lee T, Lentini L, Lerman M, Levy D, Li S, Lieberman S, Lim L, Lin C, Ling N, Lingis M, Lo M, Lovell D, Lowman D, Luca N, Lvovich S, Madison C, Madison J, Manzoni SM, Malla B, Maller J, Malloy M, Mannion M, Manos C, Marques L, Martyniuk A, Mason T, Mathus S, McAllister L, McCarthy K, McConnell K, McCormick E, McCurdy D, Stokes PMC, McGuire S, McHale I, McMonagle A, McMullen-Jackson C, Meidan E, Mellins E, Mendoza E, Mercado R, Merritt A, Michalowski L, Miettunen P, Miller M, Milojevic D, Mirizio E, Misajon E, Mitchell M, Modica R, Mohan S, Moore K, Moorthy L, Morgan S, Dewitt EM, Moss C, Moussa T, Mruk V, Murphy A, Muscal E, Nadler R, Nahal B, Nanda K, Nasah N, Nassi L, Nativ S, Natter M, Neely J, Nelson B, Newhall L, Ng L, Nicholas J, Nicolai R, Nigrovic P, Nocton J, Nolan B, Oberle E, Obispo B, O’Brien B, O’Brien T, Okeke O, Oliver M, Olson J, O’Neil K, Onel K, Orandi A, Orlando M, Osei-Onomah S, Oz R, Pagano E, Paller A, Pan N, Panupattanapong S, Pardeo M, Paredes J, Parsons A, Patel J, Pentakota K, Pepmueller P, Pfeiffer T, Phillippi K, Marafon DP, Phillippi K, Ponder L, Pooni R, Prahalad S, Pratt S, Protopapas S, Puplava B, Quach J, Quinlan-Waters M, Rabinovich C, Radhakrishna S, Rafko J, Raisian J, Rakestraw A, Ramirez C, Ramsay E, Ramsey S, Randell R, Reed A, Reed A, Reed A, Reid H, Remmel K, Repp A, Reyes A, Richmond A, Riebschleger M, Ringold S, Riordan M, Riskalla M, Ritter M, Rivas-Chacon R, Robinson A, Rodela E, Rodriquez M, Rojas K, Ronis T, Rosenkranz M, Rosolowski B, Rothermel H, Rothman D, Roth-Wojcicki E, Rouster-Stevens K, Rubinstein T, Ruth N, Saad N, Sabbagh S, Sacco E, Sadun R, Sandborg C, Sanni A, Santiago L, Sarkissian A, Savani S, Scalzi L, Schanberg L, Scharnhorst S, Schikler K, Schlefman A, Schmeling H, Schmidt K, Schmitt E, Schneider R, Schollaert-Fitch K, Schulert G, Seay T, Seper C, Shalen J, Sheets R, Shelly A, Shenoi S, Shergill K, Shirley J, Shishov M, Shivers C, Silverman E, Singer N, Sivaraman V, Sletten J, Smith A, Smith C, Smith J, Smith J, Smitherman E, Soep J, Son M, Spence S, Spiegel L, Spitznagle J, Sran R, Srinivasalu H, Stapp H, Steigerwald K, Rakovchik YS, Stern S, Stevens A, Stevens B, Stevenson R, Stewart K, Stingl C, Stokes J, Stoll M, Stringer E, Sule S, Sumner J, Sundel R, Sutter M, Syed R, Syverson G, Szymanski A, Taber S, Tal R, Tambralli A, Taneja A, Tanner T, Tapani S, Tarshish G, Tarvin S, Tate L, Taxter A, Taylor J, Terry M, Tesher M, Thatayatikom A, Thomas B, Tiffany K, Ting T, Tipp A, Toib D, Torok K, Toruner C, Tory H, Toth M, Tse S, Tubwell V, Twilt M, Uriguen S, Valcarcel T, Van Mater H, Vannoy L, Varghese C, Vasquez N, Vazzana K, Vehe R, Veiga K, Velez J, Verbsky J, Vilar G, Volpe N, von Scheven E, Vora S, Wagner J, Wagner-Weiner L, Wahezi D, Waite H, Walker J, Walters H, Muskardin TW, Waqar L, Waterfield M, Watson M, Watts A, Weiser P, Weiss J, Weiss P, Wershba E, White A, Williams C, Wise A, Woo J, Woolnough L, Wright T, Wu E, Yalcindag A, Yee M, Yen E, Yeung R, Yomogida K, Yu Q, Zapata R, Zartoshti A, Zeft A, Zeft R, Zhang Y, Zhao Y, Zhu A, Zic C. Social determinants of health influence disease activity and functional disability in Polyarticular Juvenile Idiopathic Arthritis. Pediatr Rheumatol Online J 2022; 20:18. [PMID: 35255941 PMCID: PMC8903717 DOI: 10.1186/s12969-022-00676-9] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/30/2021] [Accepted: 02/07/2022] [Indexed: 11/23/2022] Open
Abstract
BACKGROUND Social determinants of health (SDH) greatly influence outcomes during the first year of treatment in rheumatoid arthritis, a disease similar to polyarticular juvenile idiopathic arthritis (pJIA). We investigated the correlation of community poverty level and other SDH with the persistence of moderate to severe disease activity and functional disability over the first year of treatment in pJIA patients enrolled in the Childhood Arthritis and Rheumatology Research Alliance Registry. METHODS In this cohort study, unadjusted and adjusted generalized linear mixed effects models analyzed the effect of community poverty and other SDH on disease activity, using the clinical Juvenile Arthritis Disease Activity Score-10, and disability, using the Child Health Assessment Questionnaire, measured at baseline, 6, and 12 months. RESULTS One thousand six hundred eighty-four patients were identified. High community poverty (≥20% living below the federal poverty level) was associated with increased odds of functional disability (OR 1.82, 95% CI 1.28-2.60) but was not statistically significant after adjustment (aOR 1.23, 95% CI 0.81-1.86) and was not associated with increased disease activity. Non-white race/ethnicity was associated with higher disease activity (aOR 2.48, 95% CI: 1.41-4.36). Lower self-reported household income was associated with higher disease activity and persistent functional disability. Public insurance (aOR 1.56, 95% CI 1.06-2.29) and low family education (aOR 1.89, 95% CI 1.14-3.12) was associated with persistent functional disability. CONCLUSION High community poverty level was associated with persistent functional disability in unadjusted analysis but not with persistent moderate to high disease activity. Race/ethnicity and other SDH were associated with persistent disease activity and functional disability.
Collapse
Affiliation(s)
- William Daniel Soulsby
- University of California, San Francisco, 550 16th Street, 4th Floor, Box #0632, San Francisco, CA, 94158, USA.
| | - Nayimisha Balmuri
- grid.239915.50000 0001 2285 8823Hospital for Special Surgery, New York, NY USA ,grid.5386.8000000041936877XWeill Cornell Medicine, New York, NY USA
| | - Victoria Cooley
- grid.5386.8000000041936877XWeill Cornell Medicine, New York, NY USA
| | - Linda M. Gerber
- grid.5386.8000000041936877XWeill Cornell Medicine, New York, NY USA
| | - Erica Lawson
- grid.266102.10000 0001 2297 6811University of California, San Francisco, 550 16th Street, 4th Floor, Box #0632, San Francisco, CA 94158 USA
| | - Susan Goodman
- grid.239915.50000 0001 2285 8823Hospital for Special Surgery, New York, NY USA ,grid.5386.8000000041936877XWeill Cornell Medicine, New York, NY USA
| | - Karen Onel
- grid.239915.50000 0001 2285 8823Hospital for Special Surgery, New York, NY USA ,grid.5386.8000000041936877XWeill Cornell Medicine, New York, NY USA
| | - Bella Mehta
- grid.239915.50000 0001 2285 8823Hospital for Special Surgery, New York, NY USA ,grid.5386.8000000041936877XWeill Cornell Medicine, New York, NY USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
6
|
Terry M, Keith J, Oden A, Birket S. 401: Muc5b knockdown alters chronic infection outcomes in CFTR-KO rats. J Cyst Fibros 2021. [DOI: 10.1016/s1569-1993(21)01825-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
7
|
Kehm RD, Phillips KA, Daly MB, Andrulis IL, Liao Y, Ma X, Zeinomar N, MacInnis RJ, Dite GS, John EM, Buys SS, Milne RL, Hopper JL, Terry MB. Abstract PD6-05: Withdrawn. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-pd6-05] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
This abstract was withdrawn by the authors.
Citation Format: Kehm RD, Phillips K-A, Daly MB, Andrulis IL, Liao Y, Ma X, Zeinomar N, MacInnis RJ, Dite GS, John EM, Buys SS, Milne RL, Hopper JL, Terry MB. Withdrawn [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr PD6-05.
Collapse
Affiliation(s)
- RD Kehm
- Columbia University Mailman School of Public Health, New York, NY; Sir Peter MacCallum Department of Oncology, the University of Melbourne, Melbourne, Australia; School of Population and Global Health, The University of Melbourne, Melbourne, Australia; Peter MacCallum Cancer Centre, Melbourne, Australia; Fox Chase Cancer Center, Philadelphia, PA; Lunenfeld-Tanenbaum Research Institute, University of Toronto, Toronto, ON, Canada; Cancer Prevention Institute of California, Fremont, CA; Stanford University School of Medicine, Stanford, CA; Huntsman Cancer Institute, University of Utah School of Medicine, Salt Lake City, UT; Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, NY
| | - K-A Phillips
- Columbia University Mailman School of Public Health, New York, NY; Sir Peter MacCallum Department of Oncology, the University of Melbourne, Melbourne, Australia; School of Population and Global Health, The University of Melbourne, Melbourne, Australia; Peter MacCallum Cancer Centre, Melbourne, Australia; Fox Chase Cancer Center, Philadelphia, PA; Lunenfeld-Tanenbaum Research Institute, University of Toronto, Toronto, ON, Canada; Cancer Prevention Institute of California, Fremont, CA; Stanford University School of Medicine, Stanford, CA; Huntsman Cancer Institute, University of Utah School of Medicine, Salt Lake City, UT; Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, NY
| | - MB Daly
- Columbia University Mailman School of Public Health, New York, NY; Sir Peter MacCallum Department of Oncology, the University of Melbourne, Melbourne, Australia; School of Population and Global Health, The University of Melbourne, Melbourne, Australia; Peter MacCallum Cancer Centre, Melbourne, Australia; Fox Chase Cancer Center, Philadelphia, PA; Lunenfeld-Tanenbaum Research Institute, University of Toronto, Toronto, ON, Canada; Cancer Prevention Institute of California, Fremont, CA; Stanford University School of Medicine, Stanford, CA; Huntsman Cancer Institute, University of Utah School of Medicine, Salt Lake City, UT; Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, NY
| | - IL Andrulis
- Columbia University Mailman School of Public Health, New York, NY; Sir Peter MacCallum Department of Oncology, the University of Melbourne, Melbourne, Australia; School of Population and Global Health, The University of Melbourne, Melbourne, Australia; Peter MacCallum Cancer Centre, Melbourne, Australia; Fox Chase Cancer Center, Philadelphia, PA; Lunenfeld-Tanenbaum Research Institute, University of Toronto, Toronto, ON, Canada; Cancer Prevention Institute of California, Fremont, CA; Stanford University School of Medicine, Stanford, CA; Huntsman Cancer Institute, University of Utah School of Medicine, Salt Lake City, UT; Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, NY
| | - Y Liao
- Columbia University Mailman School of Public Health, New York, NY; Sir Peter MacCallum Department of Oncology, the University of Melbourne, Melbourne, Australia; School of Population and Global Health, The University of Melbourne, Melbourne, Australia; Peter MacCallum Cancer Centre, Melbourne, Australia; Fox Chase Cancer Center, Philadelphia, PA; Lunenfeld-Tanenbaum Research Institute, University of Toronto, Toronto, ON, Canada; Cancer Prevention Institute of California, Fremont, CA; Stanford University School of Medicine, Stanford, CA; Huntsman Cancer Institute, University of Utah School of Medicine, Salt Lake City, UT; Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, NY
| | - X Ma
- Columbia University Mailman School of Public Health, New York, NY; Sir Peter MacCallum Department of Oncology, the University of Melbourne, Melbourne, Australia; School of Population and Global Health, The University of Melbourne, Melbourne, Australia; Peter MacCallum Cancer Centre, Melbourne, Australia; Fox Chase Cancer Center, Philadelphia, PA; Lunenfeld-Tanenbaum Research Institute, University of Toronto, Toronto, ON, Canada; Cancer Prevention Institute of California, Fremont, CA; Stanford University School of Medicine, Stanford, CA; Huntsman Cancer Institute, University of Utah School of Medicine, Salt Lake City, UT; Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, NY
| | - N Zeinomar
- Columbia University Mailman School of Public Health, New York, NY; Sir Peter MacCallum Department of Oncology, the University of Melbourne, Melbourne, Australia; School of Population and Global Health, The University of Melbourne, Melbourne, Australia; Peter MacCallum Cancer Centre, Melbourne, Australia; Fox Chase Cancer Center, Philadelphia, PA; Lunenfeld-Tanenbaum Research Institute, University of Toronto, Toronto, ON, Canada; Cancer Prevention Institute of California, Fremont, CA; Stanford University School of Medicine, Stanford, CA; Huntsman Cancer Institute, University of Utah School of Medicine, Salt Lake City, UT; Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, NY
| | - RJ MacInnis
- Columbia University Mailman School of Public Health, New York, NY; Sir Peter MacCallum Department of Oncology, the University of Melbourne, Melbourne, Australia; School of Population and Global Health, The University of Melbourne, Melbourne, Australia; Peter MacCallum Cancer Centre, Melbourne, Australia; Fox Chase Cancer Center, Philadelphia, PA; Lunenfeld-Tanenbaum Research Institute, University of Toronto, Toronto, ON, Canada; Cancer Prevention Institute of California, Fremont, CA; Stanford University School of Medicine, Stanford, CA; Huntsman Cancer Institute, University of Utah School of Medicine, Salt Lake City, UT; Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, NY
| | - GS Dite
- Columbia University Mailman School of Public Health, New York, NY; Sir Peter MacCallum Department of Oncology, the University of Melbourne, Melbourne, Australia; School of Population and Global Health, The University of Melbourne, Melbourne, Australia; Peter MacCallum Cancer Centre, Melbourne, Australia; Fox Chase Cancer Center, Philadelphia, PA; Lunenfeld-Tanenbaum Research Institute, University of Toronto, Toronto, ON, Canada; Cancer Prevention Institute of California, Fremont, CA; Stanford University School of Medicine, Stanford, CA; Huntsman Cancer Institute, University of Utah School of Medicine, Salt Lake City, UT; Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, NY
| | - EM John
- Columbia University Mailman School of Public Health, New York, NY; Sir Peter MacCallum Department of Oncology, the University of Melbourne, Melbourne, Australia; School of Population and Global Health, The University of Melbourne, Melbourne, Australia; Peter MacCallum Cancer Centre, Melbourne, Australia; Fox Chase Cancer Center, Philadelphia, PA; Lunenfeld-Tanenbaum Research Institute, University of Toronto, Toronto, ON, Canada; Cancer Prevention Institute of California, Fremont, CA; Stanford University School of Medicine, Stanford, CA; Huntsman Cancer Institute, University of Utah School of Medicine, Salt Lake City, UT; Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, NY
| | - SS Buys
- Columbia University Mailman School of Public Health, New York, NY; Sir Peter MacCallum Department of Oncology, the University of Melbourne, Melbourne, Australia; School of Population and Global Health, The University of Melbourne, Melbourne, Australia; Peter MacCallum Cancer Centre, Melbourne, Australia; Fox Chase Cancer Center, Philadelphia, PA; Lunenfeld-Tanenbaum Research Institute, University of Toronto, Toronto, ON, Canada; Cancer Prevention Institute of California, Fremont, CA; Stanford University School of Medicine, Stanford, CA; Huntsman Cancer Institute, University of Utah School of Medicine, Salt Lake City, UT; Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, NY
| | - RL Milne
- Columbia University Mailman School of Public Health, New York, NY; Sir Peter MacCallum Department of Oncology, the University of Melbourne, Melbourne, Australia; School of Population and Global Health, The University of Melbourne, Melbourne, Australia; Peter MacCallum Cancer Centre, Melbourne, Australia; Fox Chase Cancer Center, Philadelphia, PA; Lunenfeld-Tanenbaum Research Institute, University of Toronto, Toronto, ON, Canada; Cancer Prevention Institute of California, Fremont, CA; Stanford University School of Medicine, Stanford, CA; Huntsman Cancer Institute, University of Utah School of Medicine, Salt Lake City, UT; Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, NY
| | - JL Hopper
- Columbia University Mailman School of Public Health, New York, NY; Sir Peter MacCallum Department of Oncology, the University of Melbourne, Melbourne, Australia; School of Population and Global Health, The University of Melbourne, Melbourne, Australia; Peter MacCallum Cancer Centre, Melbourne, Australia; Fox Chase Cancer Center, Philadelphia, PA; Lunenfeld-Tanenbaum Research Institute, University of Toronto, Toronto, ON, Canada; Cancer Prevention Institute of California, Fremont, CA; Stanford University School of Medicine, Stanford, CA; Huntsman Cancer Institute, University of Utah School of Medicine, Salt Lake City, UT; Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, NY
| | - MB Terry
- Columbia University Mailman School of Public Health, New York, NY; Sir Peter MacCallum Department of Oncology, the University of Melbourne, Melbourne, Australia; School of Population and Global Health, The University of Melbourne, Melbourne, Australia; Peter MacCallum Cancer Centre, Melbourne, Australia; Fox Chase Cancer Center, Philadelphia, PA; Lunenfeld-Tanenbaum Research Institute, University of Toronto, Toronto, ON, Canada; Cancer Prevention Institute of California, Fremont, CA; Stanford University School of Medicine, Stanford, CA; Huntsman Cancer Institute, University of Utah School of Medicine, Salt Lake City, UT; Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, NY
| |
Collapse
|
8
|
Terry M. Abstract ES8-3: Does breast cancer prevention need an 18th amendment? New evidence on alcohol and breast cancer. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-es8-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Epidemiological studies have consistently supported an association between alcohol consumption and breast cancer risk for many years. Breast cancer guidelines from many societies, including the American Cancer Society, have also discussed reducing alcohol consumption to help prevent breast cancer. So why aren't more women aware of this association? This talk will review the latest evidence, including more recent mechanistic studies, about the association between alcohol intake and breast cancer as well as newer data about the lack of cardio protective benefit of modest alcohol intake. What evidence do we now have about whether the association with breast cancer risk and outcomes after diagnosis varies by time in life and intensity of drinking patterns?
Citation Format: Terry M. Does breast cancer prevention need an 18th amendment? New evidence on alcohol and breast cancer [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr ES8-3.
Collapse
Affiliation(s)
- M Terry
- Columbia University, New York, NY
| |
Collapse
|
9
|
Phillips KA, Liao Y, Collins IM, Buchsbaum R, Weideman P, Bickerstaffe A, MacInnis RJ, Cuzick J, Antoniou A, Andrulis IL, John EM, Daly MB, Buys SS, Hopper JL, Terry MB. Abstract P4-09-02: Validation of iPrevent using the prospective family study cohort (ProF-SC). Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p4-09-02] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: iPrevent (https://www.petermac.org/iprevent) provides women with highly-tailored risk management information after first estimating their breast cancer (BC) risk using the established risk prediction models, IBIS and BOADICEA. iPrevent has an internal switching algorithm that governs which model is used for each woman, depending on her risk factor data (i.e. LCIS/atypical hyperplasia status, BRCA status, and cancer family history). This study assessed the calibration and discriminatory accuracy of the 10-year BC risk estimates provided by iPrevent. Methods: Subjects were 16,574 women in the ProF-SC, aged 18-70 years and without BC or bilateral mastectomy at recruitment. After 10 years follow-up, 655 women (4%) were diagnosed with invasive BC. A “batch mode” for iPrevent is not available, so the iPrevent-assigned cumulative 10-year invasive BC risks were calculated by entering self-reported risk factors at cohort entry into either the IBIS (10,169 women) or BOADICEA (6,405 women) software packages (according to the iPrevent switching algorithm). To assess calibration, the mean iPrevent-assigned risk was compared with the mean 10-year observed invasive BC incidence, using a chi-squared goodness-of-fit statistic for the whole cohort, and by quartiles of risk. To evaluate discriminatory accuracy, the overall area under the receiver operating characteristic curve (AUC) for the development of invasive BC within 10 years was computed. Data were censored at date of invasive or in situ BC diagnosis, bilateral mastectomy, death, loss to follow-up, or at 10 years of follow-up. Results: For the whole cohort, iPrevent assigned risk was well-calibrated – 690 expected BCs (E) 655 observed (O) (E/O=1.05, 95% CI: 0.98-1.14), although for women in the highest risk quartile, i.e. >6% 10-year risk, E/O=1.19, 95% CI: 1.07-1.32. The AUC was 0.70, 95% CI: 0.68-0.72. Conclusions: iPrevent is well calibrated overall and has good discriminatory accuracy for predicting 10-year BC risk, thus justifying its clinical use.
Citation Format: Phillips K-A, Liao Y, Collins IM, Buchsbaum R, Weideman P, Bickerstaffe A, MacInnis RJ, kConFab Investigators, Cuzick J, Antoniou A, Andrulis IL, John EM, Daly MB, Buys SS, Hopper JL, Terry MB. Validation of iPrevent using the prospective family study cohort (ProF-SC) [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P4-09-02.
Collapse
Affiliation(s)
- K-A Phillips
- Peter MacCallum Cancer Centre, Melbourne, Australia; Columbia University, New York; Deakin University, Geelong, Australia; The University of Melbourne, Melbourne, Australia; Cancer Council Victoria, Melbourne, Australia; Queen Mary University of London, London, United Kingdom; University of Cambridge, Cambridge, United Kingdom; Lunenfeld-Tanenbaum Research Institute, Sinai Health System, Toronto, Canada; Stanford University School of Medicine, Stanford; Fox Chase Cancer Center, Philadelphia; University of Utah, Salt Lake City
| | - Y Liao
- Peter MacCallum Cancer Centre, Melbourne, Australia; Columbia University, New York; Deakin University, Geelong, Australia; The University of Melbourne, Melbourne, Australia; Cancer Council Victoria, Melbourne, Australia; Queen Mary University of London, London, United Kingdom; University of Cambridge, Cambridge, United Kingdom; Lunenfeld-Tanenbaum Research Institute, Sinai Health System, Toronto, Canada; Stanford University School of Medicine, Stanford; Fox Chase Cancer Center, Philadelphia; University of Utah, Salt Lake City
| | - IM Collins
- Peter MacCallum Cancer Centre, Melbourne, Australia; Columbia University, New York; Deakin University, Geelong, Australia; The University of Melbourne, Melbourne, Australia; Cancer Council Victoria, Melbourne, Australia; Queen Mary University of London, London, United Kingdom; University of Cambridge, Cambridge, United Kingdom; Lunenfeld-Tanenbaum Research Institute, Sinai Health System, Toronto, Canada; Stanford University School of Medicine, Stanford; Fox Chase Cancer Center, Philadelphia; University of Utah, Salt Lake City
| | - R Buchsbaum
- Peter MacCallum Cancer Centre, Melbourne, Australia; Columbia University, New York; Deakin University, Geelong, Australia; The University of Melbourne, Melbourne, Australia; Cancer Council Victoria, Melbourne, Australia; Queen Mary University of London, London, United Kingdom; University of Cambridge, Cambridge, United Kingdom; Lunenfeld-Tanenbaum Research Institute, Sinai Health System, Toronto, Canada; Stanford University School of Medicine, Stanford; Fox Chase Cancer Center, Philadelphia; University of Utah, Salt Lake City
| | - P Weideman
- Peter MacCallum Cancer Centre, Melbourne, Australia; Columbia University, New York; Deakin University, Geelong, Australia; The University of Melbourne, Melbourne, Australia; Cancer Council Victoria, Melbourne, Australia; Queen Mary University of London, London, United Kingdom; University of Cambridge, Cambridge, United Kingdom; Lunenfeld-Tanenbaum Research Institute, Sinai Health System, Toronto, Canada; Stanford University School of Medicine, Stanford; Fox Chase Cancer Center, Philadelphia; University of Utah, Salt Lake City
| | - A Bickerstaffe
- Peter MacCallum Cancer Centre, Melbourne, Australia; Columbia University, New York; Deakin University, Geelong, Australia; The University of Melbourne, Melbourne, Australia; Cancer Council Victoria, Melbourne, Australia; Queen Mary University of London, London, United Kingdom; University of Cambridge, Cambridge, United Kingdom; Lunenfeld-Tanenbaum Research Institute, Sinai Health System, Toronto, Canada; Stanford University School of Medicine, Stanford; Fox Chase Cancer Center, Philadelphia; University of Utah, Salt Lake City
| | - RJ MacInnis
- Peter MacCallum Cancer Centre, Melbourne, Australia; Columbia University, New York; Deakin University, Geelong, Australia; The University of Melbourne, Melbourne, Australia; Cancer Council Victoria, Melbourne, Australia; Queen Mary University of London, London, United Kingdom; University of Cambridge, Cambridge, United Kingdom; Lunenfeld-Tanenbaum Research Institute, Sinai Health System, Toronto, Canada; Stanford University School of Medicine, Stanford; Fox Chase Cancer Center, Philadelphia; University of Utah, Salt Lake City
| | - J Cuzick
- Peter MacCallum Cancer Centre, Melbourne, Australia; Columbia University, New York; Deakin University, Geelong, Australia; The University of Melbourne, Melbourne, Australia; Cancer Council Victoria, Melbourne, Australia; Queen Mary University of London, London, United Kingdom; University of Cambridge, Cambridge, United Kingdom; Lunenfeld-Tanenbaum Research Institute, Sinai Health System, Toronto, Canada; Stanford University School of Medicine, Stanford; Fox Chase Cancer Center, Philadelphia; University of Utah, Salt Lake City
| | - A Antoniou
- Peter MacCallum Cancer Centre, Melbourne, Australia; Columbia University, New York; Deakin University, Geelong, Australia; The University of Melbourne, Melbourne, Australia; Cancer Council Victoria, Melbourne, Australia; Queen Mary University of London, London, United Kingdom; University of Cambridge, Cambridge, United Kingdom; Lunenfeld-Tanenbaum Research Institute, Sinai Health System, Toronto, Canada; Stanford University School of Medicine, Stanford; Fox Chase Cancer Center, Philadelphia; University of Utah, Salt Lake City
| | - IL Andrulis
- Peter MacCallum Cancer Centre, Melbourne, Australia; Columbia University, New York; Deakin University, Geelong, Australia; The University of Melbourne, Melbourne, Australia; Cancer Council Victoria, Melbourne, Australia; Queen Mary University of London, London, United Kingdom; University of Cambridge, Cambridge, United Kingdom; Lunenfeld-Tanenbaum Research Institute, Sinai Health System, Toronto, Canada; Stanford University School of Medicine, Stanford; Fox Chase Cancer Center, Philadelphia; University of Utah, Salt Lake City
| | - EM John
- Peter MacCallum Cancer Centre, Melbourne, Australia; Columbia University, New York; Deakin University, Geelong, Australia; The University of Melbourne, Melbourne, Australia; Cancer Council Victoria, Melbourne, Australia; Queen Mary University of London, London, United Kingdom; University of Cambridge, Cambridge, United Kingdom; Lunenfeld-Tanenbaum Research Institute, Sinai Health System, Toronto, Canada; Stanford University School of Medicine, Stanford; Fox Chase Cancer Center, Philadelphia; University of Utah, Salt Lake City
| | - MB Daly
- Peter MacCallum Cancer Centre, Melbourne, Australia; Columbia University, New York; Deakin University, Geelong, Australia; The University of Melbourne, Melbourne, Australia; Cancer Council Victoria, Melbourne, Australia; Queen Mary University of London, London, United Kingdom; University of Cambridge, Cambridge, United Kingdom; Lunenfeld-Tanenbaum Research Institute, Sinai Health System, Toronto, Canada; Stanford University School of Medicine, Stanford; Fox Chase Cancer Center, Philadelphia; University of Utah, Salt Lake City
| | - SS Buys
- Peter MacCallum Cancer Centre, Melbourne, Australia; Columbia University, New York; Deakin University, Geelong, Australia; The University of Melbourne, Melbourne, Australia; Cancer Council Victoria, Melbourne, Australia; Queen Mary University of London, London, United Kingdom; University of Cambridge, Cambridge, United Kingdom; Lunenfeld-Tanenbaum Research Institute, Sinai Health System, Toronto, Canada; Stanford University School of Medicine, Stanford; Fox Chase Cancer Center, Philadelphia; University of Utah, Salt Lake City
| | - JL Hopper
- Peter MacCallum Cancer Centre, Melbourne, Australia; Columbia University, New York; Deakin University, Geelong, Australia; The University of Melbourne, Melbourne, Australia; Cancer Council Victoria, Melbourne, Australia; Queen Mary University of London, London, United Kingdom; University of Cambridge, Cambridge, United Kingdom; Lunenfeld-Tanenbaum Research Institute, Sinai Health System, Toronto, Canada; Stanford University School of Medicine, Stanford; Fox Chase Cancer Center, Philadelphia; University of Utah, Salt Lake City
| | - MB Terry
- Peter MacCallum Cancer Centre, Melbourne, Australia; Columbia University, New York; Deakin University, Geelong, Australia; The University of Melbourne, Melbourne, Australia; Cancer Council Victoria, Melbourne, Australia; Queen Mary University of London, London, United Kingdom; University of Cambridge, Cambridge, United Kingdom; Lunenfeld-Tanenbaum Research Institute, Sinai Health System, Toronto, Canada; Stanford University School of Medicine, Stanford; Fox Chase Cancer Center, Philadelphia; University of Utah, Salt Lake City
| | | |
Collapse
|
10
|
Burke T, DeLoache A, Doad S, Harrington A, Homan B, McAleer E, Mamajek T, Terry M, Koszewski W, Brooks G, Nielsen S. Comparison of Orthorexia in Healthcare Professionals vs. the General Public. J Acad Nutr Diet 2018. [DOI: 10.1016/j.jand.2018.06.166] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
11
|
Zeinomar N, Phillips KA, Liao Y, MacInnis RJ, Dite GS, Daly MB, John EM, Andrulis IL, Buys SS, Hopper JL, Terry MB. Abstract P6-09-04: Benign breast disease and breast cancer risk across the spectrum of familial risk using a prospective family study cohort (ProF-SC). Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-p6-09-04] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Benign breast disease (BBD) is one of the strongest risk factors for breast cancer but it is unclear whether the strength of the association with BBD and breast cancers varies by breast cancer family history. Few studies of BBD enrich specifically for putative genetic factors by over-sampling based on family history let alone evaluate potential interactions with measures of underlying familial risk. The aim of this study was to evaluate how risk associated with BBD is modified by underlying familial risk so as to guide clinical management and risk assessment of women with BBD.
Methods: Using a prospective family study cohort of 17,154 women unaffected with breast cancer at baseline and followed by questionnaire at regular intervals, we examined the association between BBD and breast cancer risk using Cox Proportional Hazards models. We classified women as having BBD if they reported at baseline having been told by a doctor that they had BBD, such as a non-cancerous cyst or breast lump. We did not have information on histologic sub-type. We confirmed self-reported diagnosis of BBD with pathology reports in a subset of the New York cohort and found high agreement between self-reported and pathologically confirmed BBD (93.5%). We assessed multiplicative and additive interactions with underlying familial risk profile (FRP) defined as either fixed-time horizon of 1-year, or total lifetime risk, estimated from the Breast Ovarian Analysis of Disease Incidence and Carrier Estimation Algorithm (BOADICEA) model.
Results: During 176,756 person-years of follow-up (mean 10.2, maximum 23.7 years), we observed 968 incident breast cancers cases with an average age at diagnosis of 55.8 years and average age at enrollment into the cohort of 46.8 years. At baseline, 4,704 (27%) women reported having a previous diagnosis of BBD. Compared to women with no history of BBD, breast cancer risk was increased in women of all ages (HR: 1.37, 95% CI: 1.19,1.56), and in women up to age 45 years (using attained age models) (HR: 1.40, 95% CI: 1.01,1.93). In terms of recency of BBD, we found that the increased risk associated with BBD remained 21 years or more after the initial BBD diagnosis (HR: 1.37, 95% CI: 1.11, 1.68). We found no evidence for multiplicative interactions with FRP, which implies that the increase in absolute risk associated with BBD depends on a woman's FRP (Table 1).
Conclusions: Women with a history of BBD have an increased risk of breast cancer that multiplies their underlying familial risk (FRP). These results could prove to be valuable for risk counseling and clinical management.
Table 1: Cumulative Incidence of Breast Cancer to age 45, 55, and 65 by BBD and underlying FRP as measured by 10-year BOADICEA score.AgeNo BBD, <3.4 %BBD, <3.4%No BBD, ≥3.4%BBD, ≥3.4%454.6 (3.8, 5.6)6.1(4.7, 8.0)12.1 (10.2, 14.5)16.1 (13.1, 19.7)557.4 (6.3, 8.7)9.8 (7.5, 12.8)19.1 (16.6, 22.0)25.0 (21.7, 28.9)659.7 (8.2, 11.5)12.8 (9.9, 16.5)24.5 (21.8, 27.6)31.8 (28.3, 35.7)
Citation Format: Zeinomar N, Phillips KA, Liao Y, MacInnis RJ, Dite GS, Daly MB, John EM, Andrulis IL, Buys SS, Hopper JL, Terry MB. Benign breast disease and breast cancer risk across the spectrum of familial risk using a prospective family study cohort (ProF-SC) [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr P6-09-04.
Collapse
Affiliation(s)
- N Zeinomar
- Columbia University Mailman School of Public Health, New York, NY; Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, NY; The University of Melbourne, Melbourne, Australia; School of Population and Global Health, The University of Melbourne, Melbourne, Australia; Peter MacCallum Cancer Centre, Melbourne, Australia; Fox Chase Cancer Center, Philadelphia, PA; Cancer Prevention Institute of California, Fremont, CA; Stanford University School of Medicine, Stanford, CA; Lunenfeld-Tanenbaum Research Institute, University of Toronto, Toronto, ON, Canada; Huntsman Cancer Institute, University of Utah School of Medicine, Salt Lake City, UT
| | - KA Phillips
- Columbia University Mailman School of Public Health, New York, NY; Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, NY; The University of Melbourne, Melbourne, Australia; School of Population and Global Health, The University of Melbourne, Melbourne, Australia; Peter MacCallum Cancer Centre, Melbourne, Australia; Fox Chase Cancer Center, Philadelphia, PA; Cancer Prevention Institute of California, Fremont, CA; Stanford University School of Medicine, Stanford, CA; Lunenfeld-Tanenbaum Research Institute, University of Toronto, Toronto, ON, Canada; Huntsman Cancer Institute, University of Utah School of Medicine, Salt Lake City, UT
| | - Y Liao
- Columbia University Mailman School of Public Health, New York, NY; Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, NY; The University of Melbourne, Melbourne, Australia; School of Population and Global Health, The University of Melbourne, Melbourne, Australia; Peter MacCallum Cancer Centre, Melbourne, Australia; Fox Chase Cancer Center, Philadelphia, PA; Cancer Prevention Institute of California, Fremont, CA; Stanford University School of Medicine, Stanford, CA; Lunenfeld-Tanenbaum Research Institute, University of Toronto, Toronto, ON, Canada; Huntsman Cancer Institute, University of Utah School of Medicine, Salt Lake City, UT
| | - RJ MacInnis
- Columbia University Mailman School of Public Health, New York, NY; Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, NY; The University of Melbourne, Melbourne, Australia; School of Population and Global Health, The University of Melbourne, Melbourne, Australia; Peter MacCallum Cancer Centre, Melbourne, Australia; Fox Chase Cancer Center, Philadelphia, PA; Cancer Prevention Institute of California, Fremont, CA; Stanford University School of Medicine, Stanford, CA; Lunenfeld-Tanenbaum Research Institute, University of Toronto, Toronto, ON, Canada; Huntsman Cancer Institute, University of Utah School of Medicine, Salt Lake City, UT
| | - GS Dite
- Columbia University Mailman School of Public Health, New York, NY; Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, NY; The University of Melbourne, Melbourne, Australia; School of Population and Global Health, The University of Melbourne, Melbourne, Australia; Peter MacCallum Cancer Centre, Melbourne, Australia; Fox Chase Cancer Center, Philadelphia, PA; Cancer Prevention Institute of California, Fremont, CA; Stanford University School of Medicine, Stanford, CA; Lunenfeld-Tanenbaum Research Institute, University of Toronto, Toronto, ON, Canada; Huntsman Cancer Institute, University of Utah School of Medicine, Salt Lake City, UT
| | - MB Daly
- Columbia University Mailman School of Public Health, New York, NY; Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, NY; The University of Melbourne, Melbourne, Australia; School of Population and Global Health, The University of Melbourne, Melbourne, Australia; Peter MacCallum Cancer Centre, Melbourne, Australia; Fox Chase Cancer Center, Philadelphia, PA; Cancer Prevention Institute of California, Fremont, CA; Stanford University School of Medicine, Stanford, CA; Lunenfeld-Tanenbaum Research Institute, University of Toronto, Toronto, ON, Canada; Huntsman Cancer Institute, University of Utah School of Medicine, Salt Lake City, UT
| | - EM John
- Columbia University Mailman School of Public Health, New York, NY; Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, NY; The University of Melbourne, Melbourne, Australia; School of Population and Global Health, The University of Melbourne, Melbourne, Australia; Peter MacCallum Cancer Centre, Melbourne, Australia; Fox Chase Cancer Center, Philadelphia, PA; Cancer Prevention Institute of California, Fremont, CA; Stanford University School of Medicine, Stanford, CA; Lunenfeld-Tanenbaum Research Institute, University of Toronto, Toronto, ON, Canada; Huntsman Cancer Institute, University of Utah School of Medicine, Salt Lake City, UT
| | - IL Andrulis
- Columbia University Mailman School of Public Health, New York, NY; Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, NY; The University of Melbourne, Melbourne, Australia; School of Population and Global Health, The University of Melbourne, Melbourne, Australia; Peter MacCallum Cancer Centre, Melbourne, Australia; Fox Chase Cancer Center, Philadelphia, PA; Cancer Prevention Institute of California, Fremont, CA; Stanford University School of Medicine, Stanford, CA; Lunenfeld-Tanenbaum Research Institute, University of Toronto, Toronto, ON, Canada; Huntsman Cancer Institute, University of Utah School of Medicine, Salt Lake City, UT
| | - SS Buys
- Columbia University Mailman School of Public Health, New York, NY; Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, NY; The University of Melbourne, Melbourne, Australia; School of Population and Global Health, The University of Melbourne, Melbourne, Australia; Peter MacCallum Cancer Centre, Melbourne, Australia; Fox Chase Cancer Center, Philadelphia, PA; Cancer Prevention Institute of California, Fremont, CA; Stanford University School of Medicine, Stanford, CA; Lunenfeld-Tanenbaum Research Institute, University of Toronto, Toronto, ON, Canada; Huntsman Cancer Institute, University of Utah School of Medicine, Salt Lake City, UT
| | - JL Hopper
- Columbia University Mailman School of Public Health, New York, NY; Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, NY; The University of Melbourne, Melbourne, Australia; School of Population and Global Health, The University of Melbourne, Melbourne, Australia; Peter MacCallum Cancer Centre, Melbourne, Australia; Fox Chase Cancer Center, Philadelphia, PA; Cancer Prevention Institute of California, Fremont, CA; Stanford University School of Medicine, Stanford, CA; Lunenfeld-Tanenbaum Research Institute, University of Toronto, Toronto, ON, Canada; Huntsman Cancer Institute, University of Utah School of Medicine, Salt Lake City, UT
| | - MB Terry
- Columbia University Mailman School of Public Health, New York, NY; Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, NY; The University of Melbourne, Melbourne, Australia; School of Population and Global Health, The University of Melbourne, Melbourne, Australia; Peter MacCallum Cancer Centre, Melbourne, Australia; Fox Chase Cancer Center, Philadelphia, PA; Cancer Prevention Institute of California, Fremont, CA; Stanford University School of Medicine, Stanford, CA; Lunenfeld-Tanenbaum Research Institute, University of Toronto, Toronto, ON, Canada; Huntsman Cancer Institute, University of Utah School of Medicine, Salt Lake City, UT
| |
Collapse
|
12
|
Terry MB, Phillips KA, Daly MB, Andrulis IL, Liao Y, Ma X, Zeinomar N, MacInnis RJ, Dite GS, John EM, Buys SS, Hopper JL. Abstract P6-09-01: Risk-reducing oophorectomy and breast cancer risk across the spectrum of familial risk using a prospective family study cohort (ProF-SC). Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-p6-09-01] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Whether risk-reducing salpingo oophorectomy (RRSO) reduces breast cancer risk in addition to reducing ovarian cancer risk is controversial with some arguing that the previous evidence of a reduction in breast cancer risk from RRSO was due to bias. Evidence from independent prospective cohorts of high-risk women is needed to resolve this controversy.
Methods: Using a prospective family study cohort of 17,810 women unaffected with breast cancer at baseline, we examined the association between RRSO and breast cancer risk using Cox Proportional Hazards models. We compared results estimating RRSO as a non-time-dependent variable to results treating RRSO as a time-dependent variable, because failing to account for the time-varying nature of a covariate person- time prior to RRSO, should it exist, will incorrectly attribute the cancer-free person-time to RRSO. We separately examined the association with RRSO in BRCA1 and BRCA2 mutation carriers and non-carriers, and further performed gene-stratified analyses in women with BRCA1 and BRCA2 only. We also assessed multiplicative interactions with underlying familial risk profile (FRP), defined as total lifetime risk estimated from the Breast Ovarian Analysis of Disease Incidence and Carrier Estimation Algorithm (BOADICEA) model.
Results: During a median 10.7 years of follow-up (maximum 23.7 years), we observed 1,040 incident cases of breast cancer with an average age at diagnosis of 55.8 years and average age at enrollment into the cohort of 46.8 years. A total of 2434 (14%) women reported at baseline having a RRSO. We observed decreased risk of breast cancer associated with RRSO for both BRCA1(N= 650) and BRCA2(N=557) mutation carriers when RRSO was treated as a fixed covariate (HR= 0.60, 95% CI=0.40-0.92 and HR= 0.40, 95%CI = 0.23-0.69, respectively). In contrast, when we treated RRSO as a time-varying covariate, for both BRCA1 and BRCA2 carriers, we no longer observed a decreased risk for BRCA1 and BRCA2 carriers (HR= 1.67, 95% CI=1.05-2.67 and HR= 0.97, 95%CI = 0.53-1.80, respectively). There was no association between RRSO and breast cancer risk for non-carriers (N=16,603), whether we treated RRSO as a fixed or time varying covariate (HR= 0.88, 95% CI=0.72-1.08 and HR= 1.06, 95%CI = 0.85-1.30, respectively).
Conclusions: Our findings provide an independent replication that the reduced risk of breast cancer previously observed in BRCA1 and BRCA2 mutation carrier women may be from bias in counting person-time. Clinical management of high-risk women should counsel based on the reduced risk of ovarian cancer from RRSO, but not breast cancer.
Citation Format: Terry MB, Phillips KA, Daly MB, Andrulis IL, Liao Y, Ma X, Zeinomar N, MacInnis RJ, Dite GS, John EM, Buys SS, Hopper JL. Risk-reducing oophorectomy and breast cancer risk across the spectrum of familial risk using a prospective family study cohort (ProF-SC) [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr P6-09-01.
Collapse
Affiliation(s)
- MB Terry
- Columbia University Mailman School of Public Health, New York, NY; Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, NY; The University of Melbourne, Melbourne, Australia; School of Population and Global Health, The University of Melbourne, Melbourne, Australia; Peter MacCallum Cancer Centre, Melbourne, Australia; Fox Chase Cancer Center, Philadelphia, PA; Cancer Prevention Institute of California, Fremont, CA; Stanford University School of Medicine, Stanford, CA; Lunenfeld-Tanenbaum Research Institute, University of Toronto, Toronto, ON, Canada; Huntsman Cancer Institute, University of Utah School of Medicine, Salt Lake City, UT
| | - KA Phillips
- Columbia University Mailman School of Public Health, New York, NY; Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, NY; The University of Melbourne, Melbourne, Australia; School of Population and Global Health, The University of Melbourne, Melbourne, Australia; Peter MacCallum Cancer Centre, Melbourne, Australia; Fox Chase Cancer Center, Philadelphia, PA; Cancer Prevention Institute of California, Fremont, CA; Stanford University School of Medicine, Stanford, CA; Lunenfeld-Tanenbaum Research Institute, University of Toronto, Toronto, ON, Canada; Huntsman Cancer Institute, University of Utah School of Medicine, Salt Lake City, UT
| | - MB Daly
- Columbia University Mailman School of Public Health, New York, NY; Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, NY; The University of Melbourne, Melbourne, Australia; School of Population and Global Health, The University of Melbourne, Melbourne, Australia; Peter MacCallum Cancer Centre, Melbourne, Australia; Fox Chase Cancer Center, Philadelphia, PA; Cancer Prevention Institute of California, Fremont, CA; Stanford University School of Medicine, Stanford, CA; Lunenfeld-Tanenbaum Research Institute, University of Toronto, Toronto, ON, Canada; Huntsman Cancer Institute, University of Utah School of Medicine, Salt Lake City, UT
| | - IL Andrulis
- Columbia University Mailman School of Public Health, New York, NY; Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, NY; The University of Melbourne, Melbourne, Australia; School of Population and Global Health, The University of Melbourne, Melbourne, Australia; Peter MacCallum Cancer Centre, Melbourne, Australia; Fox Chase Cancer Center, Philadelphia, PA; Cancer Prevention Institute of California, Fremont, CA; Stanford University School of Medicine, Stanford, CA; Lunenfeld-Tanenbaum Research Institute, University of Toronto, Toronto, ON, Canada; Huntsman Cancer Institute, University of Utah School of Medicine, Salt Lake City, UT
| | - Y Liao
- Columbia University Mailman School of Public Health, New York, NY; Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, NY; The University of Melbourne, Melbourne, Australia; School of Population and Global Health, The University of Melbourne, Melbourne, Australia; Peter MacCallum Cancer Centre, Melbourne, Australia; Fox Chase Cancer Center, Philadelphia, PA; Cancer Prevention Institute of California, Fremont, CA; Stanford University School of Medicine, Stanford, CA; Lunenfeld-Tanenbaum Research Institute, University of Toronto, Toronto, ON, Canada; Huntsman Cancer Institute, University of Utah School of Medicine, Salt Lake City, UT
| | - X Ma
- Columbia University Mailman School of Public Health, New York, NY; Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, NY; The University of Melbourne, Melbourne, Australia; School of Population and Global Health, The University of Melbourne, Melbourne, Australia; Peter MacCallum Cancer Centre, Melbourne, Australia; Fox Chase Cancer Center, Philadelphia, PA; Cancer Prevention Institute of California, Fremont, CA; Stanford University School of Medicine, Stanford, CA; Lunenfeld-Tanenbaum Research Institute, University of Toronto, Toronto, ON, Canada; Huntsman Cancer Institute, University of Utah School of Medicine, Salt Lake City, UT
| | - N Zeinomar
- Columbia University Mailman School of Public Health, New York, NY; Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, NY; The University of Melbourne, Melbourne, Australia; School of Population and Global Health, The University of Melbourne, Melbourne, Australia; Peter MacCallum Cancer Centre, Melbourne, Australia; Fox Chase Cancer Center, Philadelphia, PA; Cancer Prevention Institute of California, Fremont, CA; Stanford University School of Medicine, Stanford, CA; Lunenfeld-Tanenbaum Research Institute, University of Toronto, Toronto, ON, Canada; Huntsman Cancer Institute, University of Utah School of Medicine, Salt Lake City, UT
| | - RJ MacInnis
- Columbia University Mailman School of Public Health, New York, NY; Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, NY; The University of Melbourne, Melbourne, Australia; School of Population and Global Health, The University of Melbourne, Melbourne, Australia; Peter MacCallum Cancer Centre, Melbourne, Australia; Fox Chase Cancer Center, Philadelphia, PA; Cancer Prevention Institute of California, Fremont, CA; Stanford University School of Medicine, Stanford, CA; Lunenfeld-Tanenbaum Research Institute, University of Toronto, Toronto, ON, Canada; Huntsman Cancer Institute, University of Utah School of Medicine, Salt Lake City, UT
| | - GS Dite
- Columbia University Mailman School of Public Health, New York, NY; Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, NY; The University of Melbourne, Melbourne, Australia; School of Population and Global Health, The University of Melbourne, Melbourne, Australia; Peter MacCallum Cancer Centre, Melbourne, Australia; Fox Chase Cancer Center, Philadelphia, PA; Cancer Prevention Institute of California, Fremont, CA; Stanford University School of Medicine, Stanford, CA; Lunenfeld-Tanenbaum Research Institute, University of Toronto, Toronto, ON, Canada; Huntsman Cancer Institute, University of Utah School of Medicine, Salt Lake City, UT
| | - EM John
- Columbia University Mailman School of Public Health, New York, NY; Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, NY; The University of Melbourne, Melbourne, Australia; School of Population and Global Health, The University of Melbourne, Melbourne, Australia; Peter MacCallum Cancer Centre, Melbourne, Australia; Fox Chase Cancer Center, Philadelphia, PA; Cancer Prevention Institute of California, Fremont, CA; Stanford University School of Medicine, Stanford, CA; Lunenfeld-Tanenbaum Research Institute, University of Toronto, Toronto, ON, Canada; Huntsman Cancer Institute, University of Utah School of Medicine, Salt Lake City, UT
| | - SS Buys
- Columbia University Mailman School of Public Health, New York, NY; Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, NY; The University of Melbourne, Melbourne, Australia; School of Population and Global Health, The University of Melbourne, Melbourne, Australia; Peter MacCallum Cancer Centre, Melbourne, Australia; Fox Chase Cancer Center, Philadelphia, PA; Cancer Prevention Institute of California, Fremont, CA; Stanford University School of Medicine, Stanford, CA; Lunenfeld-Tanenbaum Research Institute, University of Toronto, Toronto, ON, Canada; Huntsman Cancer Institute, University of Utah School of Medicine, Salt Lake City, UT
| | - JL Hopper
- Columbia University Mailman School of Public Health, New York, NY; Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, NY; The University of Melbourne, Melbourne, Australia; School of Population and Global Health, The University of Melbourne, Melbourne, Australia; Peter MacCallum Cancer Centre, Melbourne, Australia; Fox Chase Cancer Center, Philadelphia, PA; Cancer Prevention Institute of California, Fremont, CA; Stanford University School of Medicine, Stanford, CA; Lunenfeld-Tanenbaum Research Institute, University of Toronto, Toronto, ON, Canada; Huntsman Cancer Institute, University of Utah School of Medicine, Salt Lake City, UT
| |
Collapse
|
13
|
Crew KD, Anderson G, Hershman DL, Terry MB, Tehranifar P, Lew DL, Yee M, Brown EA, Kairouz SS, Minasian LM, Ford L, Neuhouser ML, Arun BK, Brown PH. Abstract P5-15-02: Withdrawn. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-p5-15-02] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
This abstract was withdrawn by the authors.
Collapse
Affiliation(s)
- KD Crew
- Columbia University Medical Center, New York, NY; Fred Hutchinson Cancer Research Center, Seattle, WA; SWOG Statistics and Data Management Center, Seattle, WA; Beaumont NCORP, William Beaumont Hospital, Troy, MI; Heartland NCORP, Cancer Care Specialists of Central Illinois, Decatur, IL; National Cancer Institute, Bethesda, MD; MD Anderson Cancer Center, Houston, TX
| | - G Anderson
- Columbia University Medical Center, New York, NY; Fred Hutchinson Cancer Research Center, Seattle, WA; SWOG Statistics and Data Management Center, Seattle, WA; Beaumont NCORP, William Beaumont Hospital, Troy, MI; Heartland NCORP, Cancer Care Specialists of Central Illinois, Decatur, IL; National Cancer Institute, Bethesda, MD; MD Anderson Cancer Center, Houston, TX
| | - DL Hershman
- Columbia University Medical Center, New York, NY; Fred Hutchinson Cancer Research Center, Seattle, WA; SWOG Statistics and Data Management Center, Seattle, WA; Beaumont NCORP, William Beaumont Hospital, Troy, MI; Heartland NCORP, Cancer Care Specialists of Central Illinois, Decatur, IL; National Cancer Institute, Bethesda, MD; MD Anderson Cancer Center, Houston, TX
| | - MB Terry
- Columbia University Medical Center, New York, NY; Fred Hutchinson Cancer Research Center, Seattle, WA; SWOG Statistics and Data Management Center, Seattle, WA; Beaumont NCORP, William Beaumont Hospital, Troy, MI; Heartland NCORP, Cancer Care Specialists of Central Illinois, Decatur, IL; National Cancer Institute, Bethesda, MD; MD Anderson Cancer Center, Houston, TX
| | - P Tehranifar
- Columbia University Medical Center, New York, NY; Fred Hutchinson Cancer Research Center, Seattle, WA; SWOG Statistics and Data Management Center, Seattle, WA; Beaumont NCORP, William Beaumont Hospital, Troy, MI; Heartland NCORP, Cancer Care Specialists of Central Illinois, Decatur, IL; National Cancer Institute, Bethesda, MD; MD Anderson Cancer Center, Houston, TX
| | - DL Lew
- Columbia University Medical Center, New York, NY; Fred Hutchinson Cancer Research Center, Seattle, WA; SWOG Statistics and Data Management Center, Seattle, WA; Beaumont NCORP, William Beaumont Hospital, Troy, MI; Heartland NCORP, Cancer Care Specialists of Central Illinois, Decatur, IL; National Cancer Institute, Bethesda, MD; MD Anderson Cancer Center, Houston, TX
| | - M Yee
- Columbia University Medical Center, New York, NY; Fred Hutchinson Cancer Research Center, Seattle, WA; SWOG Statistics and Data Management Center, Seattle, WA; Beaumont NCORP, William Beaumont Hospital, Troy, MI; Heartland NCORP, Cancer Care Specialists of Central Illinois, Decatur, IL; National Cancer Institute, Bethesda, MD; MD Anderson Cancer Center, Houston, TX
| | - EA Brown
- Columbia University Medical Center, New York, NY; Fred Hutchinson Cancer Research Center, Seattle, WA; SWOG Statistics and Data Management Center, Seattle, WA; Beaumont NCORP, William Beaumont Hospital, Troy, MI; Heartland NCORP, Cancer Care Specialists of Central Illinois, Decatur, IL; National Cancer Institute, Bethesda, MD; MD Anderson Cancer Center, Houston, TX
| | - SS Kairouz
- Columbia University Medical Center, New York, NY; Fred Hutchinson Cancer Research Center, Seattle, WA; SWOG Statistics and Data Management Center, Seattle, WA; Beaumont NCORP, William Beaumont Hospital, Troy, MI; Heartland NCORP, Cancer Care Specialists of Central Illinois, Decatur, IL; National Cancer Institute, Bethesda, MD; MD Anderson Cancer Center, Houston, TX
| | - LM Minasian
- Columbia University Medical Center, New York, NY; Fred Hutchinson Cancer Research Center, Seattle, WA; SWOG Statistics and Data Management Center, Seattle, WA; Beaumont NCORP, William Beaumont Hospital, Troy, MI; Heartland NCORP, Cancer Care Specialists of Central Illinois, Decatur, IL; National Cancer Institute, Bethesda, MD; MD Anderson Cancer Center, Houston, TX
| | - L Ford
- Columbia University Medical Center, New York, NY; Fred Hutchinson Cancer Research Center, Seattle, WA; SWOG Statistics and Data Management Center, Seattle, WA; Beaumont NCORP, William Beaumont Hospital, Troy, MI; Heartland NCORP, Cancer Care Specialists of Central Illinois, Decatur, IL; National Cancer Institute, Bethesda, MD; MD Anderson Cancer Center, Houston, TX
| | - ML Neuhouser
- Columbia University Medical Center, New York, NY; Fred Hutchinson Cancer Research Center, Seattle, WA; SWOG Statistics and Data Management Center, Seattle, WA; Beaumont NCORP, William Beaumont Hospital, Troy, MI; Heartland NCORP, Cancer Care Specialists of Central Illinois, Decatur, IL; National Cancer Institute, Bethesda, MD; MD Anderson Cancer Center, Houston, TX
| | - BK Arun
- Columbia University Medical Center, New York, NY; Fred Hutchinson Cancer Research Center, Seattle, WA; SWOG Statistics and Data Management Center, Seattle, WA; Beaumont NCORP, William Beaumont Hospital, Troy, MI; Heartland NCORP, Cancer Care Specialists of Central Illinois, Decatur, IL; National Cancer Institute, Bethesda, MD; MD Anderson Cancer Center, Houston, TX
| | - PH Brown
- Columbia University Medical Center, New York, NY; Fred Hutchinson Cancer Research Center, Seattle, WA; SWOG Statistics and Data Management Center, Seattle, WA; Beaumont NCORP, William Beaumont Hospital, Troy, MI; Heartland NCORP, Cancer Care Specialists of Central Illinois, Decatur, IL; National Cancer Institute, Bethesda, MD; MD Anderson Cancer Center, Houston, TX
| |
Collapse
|
14
|
Leoce NM, Terry MB, Jin Z, Kushi LH, Roh JM, Laurent CA. Abstract P3-09-06: Predicting cardiovascular versus cancer mortality in a cohort of breast cancer survivors. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-p3-09-06] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Given improved survival after breast cancer diagnosis for women with non-metastatic disease, many will likely survive their disease and ultimately die from causes other than breast cancer, the most frequent being cardiovascular disease. There are numerous risk prediction models, such as the Framingham risk score, to identify persons who are at high risk for a cardiovascular event or death. However, these models have been developed for use in the general population and have not been validated in any cohorts of cancer survivors, who are at increased risk for competing causes of death. We evaluated commonly used risk models for cardiovascular events on a contemporary cohort of breast cancer survivors, and developed a new risk model to simultaneously predict the likelihood of death from breast cancer or cardiovascular disease (CVD).
Methods: We included all women diagnosed with stage I-III breast cancer between January 1, 2000 and December 31, 2010 in Kaiser Permanente Northern California (KPNC) with follow-up through April 30, 2015. Specifically, we extracted from KPNC clinical and other databases: breast cancer characteristics, cardiovascular risk factors (cholesterol, blood pressure (BP), diabetes, BP lowering medication, smoking status), cardiovascular events, and cause of death. We assessed discrimination for the Framingham, CORE and SCOREOP cardiovascular risk models using the area under the receiver operating characteristic curve (AUC), and calibration by comparing the observed to the expected events. We used a multi-state model based on Cox cause specific hazards (CSH) to jointly model the risk of cardiovascular death and breast cancer death, while accounting for all other causes.
Results: In this population of 20,462 KPNC breast cancer survivors with a median follow-up of 7.5 years, there were 695 cardiovascular and 842 breast cancer deaths. The existing cardiovascular risk models discriminated adequately (AUCs ranging 0.64 – 0.78), though models predicting cardiovascular mortality tended to over-predict, while those predicting non-fatal events tended to under-predict. Models developed to predict in a shorter time frame (<5 years), performed slightly better (E/O ratios of 1.08 and 1.18 for Framingham predicting events in the next 2 and 4 years, respectively). In our multi-state model, many of the traditional cardiovascular risk factors were no longer statistically significant (diabetes, BP) in predicting cardiovascular mortality, while the breast cancer characteristics (grade, tumor size, nodal involvement), as well as a prior history of CVD, were most useful in predicting cause of death. The model performed well, with AUCs of 0.85 (95% CI 0.83, 0.86) for 5-year risk of cardiovascular death and 0.85 (95% CI 0.84, 0.87) for breast cancer death.
Conclusion: If replicated in an independent cohort, our model suggests that breast cancer characteristics can help predict overall mortality as well as cardiovascular death. Given the risk of cardiovascular death in the population of breast cancer survivors, joint modeling of breast and cardiovascular mortality is warranted.
Citation Format: Leoce NM, Terry MB, Jin Z, Kushi LH, Roh JM, Laurent CA. Predicting cardiovascular versus cancer mortality in a cohort of breast cancer survivors [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr P3-09-06.
Collapse
Affiliation(s)
- NM Leoce
- Columbia University, New York, NY; Kaiser Permanente Northern California, Oakland, CA
| | - MB Terry
- Columbia University, New York, NY; Kaiser Permanente Northern California, Oakland, CA
| | - Z Jin
- Columbia University, New York, NY; Kaiser Permanente Northern California, Oakland, CA
| | - LH Kushi
- Columbia University, New York, NY; Kaiser Permanente Northern California, Oakland, CA
| | - JM Roh
- Columbia University, New York, NY; Kaiser Permanente Northern California, Oakland, CA
| | - CA Laurent
- Columbia University, New York, NY; Kaiser Permanente Northern California, Oakland, CA
| |
Collapse
|
15
|
Terry MB, Phillips KA, Liao Y, MacInnis RJ, Dite GS, Daly MB, John EM, Andrulis IL, Buys SS, Buchsbaum R, Hopper JL. Abstract P2-06-01: Non-genetic risk factors improve accuracy of breast cancer risk assessment for women at high familial risk: Comparison of risk estimation models using the prospective family study cohort (ProF-SC). Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p2-06-01] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
This abstract was withdrawn by the authors.
Collapse
Affiliation(s)
- MB Terry
- Columbia University Mailman School of Public Health, New York, NY; Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, NY; The University of Melbourne, Melbourne, Australia; School of Population and Global Health, The University of Melbourne, Melbourne, Australia; Peter MacCallum Cancer Centre, Melbourne, Australia; Fox Chase Cancer Center, Philadelphia, PA; Cancer Prevention Institute of California, Fremont, CA; Stanford University School of Medicine, Stanford, CA; Lunenfeld-Tanenbaum Research Institute, University of Toronto, Toronto, ON, Canada; Huntsman Cancer Institute, University of Utah School of Medicine, Salt Lake City, UT
| | - K-A Phillips
- Columbia University Mailman School of Public Health, New York, NY; Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, NY; The University of Melbourne, Melbourne, Australia; School of Population and Global Health, The University of Melbourne, Melbourne, Australia; Peter MacCallum Cancer Centre, Melbourne, Australia; Fox Chase Cancer Center, Philadelphia, PA; Cancer Prevention Institute of California, Fremont, CA; Stanford University School of Medicine, Stanford, CA; Lunenfeld-Tanenbaum Research Institute, University of Toronto, Toronto, ON, Canada; Huntsman Cancer Institute, University of Utah School of Medicine, Salt Lake City, UT
| | - Y Liao
- Columbia University Mailman School of Public Health, New York, NY; Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, NY; The University of Melbourne, Melbourne, Australia; School of Population and Global Health, The University of Melbourne, Melbourne, Australia; Peter MacCallum Cancer Centre, Melbourne, Australia; Fox Chase Cancer Center, Philadelphia, PA; Cancer Prevention Institute of California, Fremont, CA; Stanford University School of Medicine, Stanford, CA; Lunenfeld-Tanenbaum Research Institute, University of Toronto, Toronto, ON, Canada; Huntsman Cancer Institute, University of Utah School of Medicine, Salt Lake City, UT
| | - RJ MacInnis
- Columbia University Mailman School of Public Health, New York, NY; Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, NY; The University of Melbourne, Melbourne, Australia; School of Population and Global Health, The University of Melbourne, Melbourne, Australia; Peter MacCallum Cancer Centre, Melbourne, Australia; Fox Chase Cancer Center, Philadelphia, PA; Cancer Prevention Institute of California, Fremont, CA; Stanford University School of Medicine, Stanford, CA; Lunenfeld-Tanenbaum Research Institute, University of Toronto, Toronto, ON, Canada; Huntsman Cancer Institute, University of Utah School of Medicine, Salt Lake City, UT
| | - GS Dite
- Columbia University Mailman School of Public Health, New York, NY; Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, NY; The University of Melbourne, Melbourne, Australia; School of Population and Global Health, The University of Melbourne, Melbourne, Australia; Peter MacCallum Cancer Centre, Melbourne, Australia; Fox Chase Cancer Center, Philadelphia, PA; Cancer Prevention Institute of California, Fremont, CA; Stanford University School of Medicine, Stanford, CA; Lunenfeld-Tanenbaum Research Institute, University of Toronto, Toronto, ON, Canada; Huntsman Cancer Institute, University of Utah School of Medicine, Salt Lake City, UT
| | - MB Daly
- Columbia University Mailman School of Public Health, New York, NY; Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, NY; The University of Melbourne, Melbourne, Australia; School of Population and Global Health, The University of Melbourne, Melbourne, Australia; Peter MacCallum Cancer Centre, Melbourne, Australia; Fox Chase Cancer Center, Philadelphia, PA; Cancer Prevention Institute of California, Fremont, CA; Stanford University School of Medicine, Stanford, CA; Lunenfeld-Tanenbaum Research Institute, University of Toronto, Toronto, ON, Canada; Huntsman Cancer Institute, University of Utah School of Medicine, Salt Lake City, UT
| | - EM John
- Columbia University Mailman School of Public Health, New York, NY; Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, NY; The University of Melbourne, Melbourne, Australia; School of Population and Global Health, The University of Melbourne, Melbourne, Australia; Peter MacCallum Cancer Centre, Melbourne, Australia; Fox Chase Cancer Center, Philadelphia, PA; Cancer Prevention Institute of California, Fremont, CA; Stanford University School of Medicine, Stanford, CA; Lunenfeld-Tanenbaum Research Institute, University of Toronto, Toronto, ON, Canada; Huntsman Cancer Institute, University of Utah School of Medicine, Salt Lake City, UT
| | - IL Andrulis
- Columbia University Mailman School of Public Health, New York, NY; Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, NY; The University of Melbourne, Melbourne, Australia; School of Population and Global Health, The University of Melbourne, Melbourne, Australia; Peter MacCallum Cancer Centre, Melbourne, Australia; Fox Chase Cancer Center, Philadelphia, PA; Cancer Prevention Institute of California, Fremont, CA; Stanford University School of Medicine, Stanford, CA; Lunenfeld-Tanenbaum Research Institute, University of Toronto, Toronto, ON, Canada; Huntsman Cancer Institute, University of Utah School of Medicine, Salt Lake City, UT
| | - SS Buys
- Columbia University Mailman School of Public Health, New York, NY; Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, NY; The University of Melbourne, Melbourne, Australia; School of Population and Global Health, The University of Melbourne, Melbourne, Australia; Peter MacCallum Cancer Centre, Melbourne, Australia; Fox Chase Cancer Center, Philadelphia, PA; Cancer Prevention Institute of California, Fremont, CA; Stanford University School of Medicine, Stanford, CA; Lunenfeld-Tanenbaum Research Institute, University of Toronto, Toronto, ON, Canada; Huntsman Cancer Institute, University of Utah School of Medicine, Salt Lake City, UT
| | - R Buchsbaum
- Columbia University Mailman School of Public Health, New York, NY; Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, NY; The University of Melbourne, Melbourne, Australia; School of Population and Global Health, The University of Melbourne, Melbourne, Australia; Peter MacCallum Cancer Centre, Melbourne, Australia; Fox Chase Cancer Center, Philadelphia, PA; Cancer Prevention Institute of California, Fremont, CA; Stanford University School of Medicine, Stanford, CA; Lunenfeld-Tanenbaum Research Institute, University of Toronto, Toronto, ON, Canada; Huntsman Cancer Institute, University of Utah School of Medicine, Salt Lake City, UT
| | - JL Hopper
- Columbia University Mailman School of Public Health, New York, NY; Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, NY; The University of Melbourne, Melbourne, Australia; School of Population and Global Health, The University of Melbourne, Melbourne, Australia; Peter MacCallum Cancer Centre, Melbourne, Australia; Fox Chase Cancer Center, Philadelphia, PA; Cancer Prevention Institute of California, Fremont, CA; Stanford University School of Medicine, Stanford, CA; Lunenfeld-Tanenbaum Research Institute, University of Toronto, Toronto, ON, Canada; Huntsman Cancer Institute, University of Utah School of Medicine, Salt Lake City, UT
| |
Collapse
|
16
|
Terry MB, Dite GS, Phillips KA, Andrulis IL, John EM, Daly MB, Buys SS, Hopper JL. Abstract P5-08-05: Prospective family cohort analyses of gene-environment interactions in breast cancer: Body mass index. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p5-08-05] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
This abstract was not presented at the symposium.
Collapse
Affiliation(s)
- MB Terry
- Columbia University Mailman School of Public Health, New York, NY; The University of Melbourne, Carlton, Victoria, Australia; Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; Mount Sinai Hospital, Toronto, ON, Canada; Cancer Prevention Institute of California, Fremont, CA; Stanford University School of Medicine, Stanford, CA; Fox Chase Cancer Center, Philadelphia, PA; University of Utah School of Medicine, Salt Lake City, UT
| | - GS Dite
- Columbia University Mailman School of Public Health, New York, NY; The University of Melbourne, Carlton, Victoria, Australia; Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; Mount Sinai Hospital, Toronto, ON, Canada; Cancer Prevention Institute of California, Fremont, CA; Stanford University School of Medicine, Stanford, CA; Fox Chase Cancer Center, Philadelphia, PA; University of Utah School of Medicine, Salt Lake City, UT
| | - K-A Phillips
- Columbia University Mailman School of Public Health, New York, NY; The University of Melbourne, Carlton, Victoria, Australia; Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; Mount Sinai Hospital, Toronto, ON, Canada; Cancer Prevention Institute of California, Fremont, CA; Stanford University School of Medicine, Stanford, CA; Fox Chase Cancer Center, Philadelphia, PA; University of Utah School of Medicine, Salt Lake City, UT
| | - IL Andrulis
- Columbia University Mailman School of Public Health, New York, NY; The University of Melbourne, Carlton, Victoria, Australia; Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; Mount Sinai Hospital, Toronto, ON, Canada; Cancer Prevention Institute of California, Fremont, CA; Stanford University School of Medicine, Stanford, CA; Fox Chase Cancer Center, Philadelphia, PA; University of Utah School of Medicine, Salt Lake City, UT
| | - EM John
- Columbia University Mailman School of Public Health, New York, NY; The University of Melbourne, Carlton, Victoria, Australia; Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; Mount Sinai Hospital, Toronto, ON, Canada; Cancer Prevention Institute of California, Fremont, CA; Stanford University School of Medicine, Stanford, CA; Fox Chase Cancer Center, Philadelphia, PA; University of Utah School of Medicine, Salt Lake City, UT
| | - MB Daly
- Columbia University Mailman School of Public Health, New York, NY; The University of Melbourne, Carlton, Victoria, Australia; Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; Mount Sinai Hospital, Toronto, ON, Canada; Cancer Prevention Institute of California, Fremont, CA; Stanford University School of Medicine, Stanford, CA; Fox Chase Cancer Center, Philadelphia, PA; University of Utah School of Medicine, Salt Lake City, UT
| | - SS Buys
- Columbia University Mailman School of Public Health, New York, NY; The University of Melbourne, Carlton, Victoria, Australia; Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; Mount Sinai Hospital, Toronto, ON, Canada; Cancer Prevention Institute of California, Fremont, CA; Stanford University School of Medicine, Stanford, CA; Fox Chase Cancer Center, Philadelphia, PA; University of Utah School of Medicine, Salt Lake City, UT
| | - JL Hopper
- Columbia University Mailman School of Public Health, New York, NY; The University of Melbourne, Carlton, Victoria, Australia; Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; Mount Sinai Hospital, Toronto, ON, Canada; Cancer Prevention Institute of California, Fremont, CA; Stanford University School of Medicine, Stanford, CA; Fox Chase Cancer Center, Philadelphia, PA; University of Utah School of Medicine, Salt Lake City, UT
| |
Collapse
|
17
|
Metse AP, Wiggers J, Wye P, Wolfenden L, Freund M, Clancy R, Stockings E, Terry M, Allan J, Colyvas K, Prochaska JJ, Bowman JA. An integrated smoking intervention for mental health patients: a randomised controlled trial. Eur J Public Health 2016. [DOI: 10.1093/eurpub/ckw172.067] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
18
|
Ho J, Houghton L, Salem W, Ma L, Kumar A, Kalra B, Terry M, Stanczyk F. Antimüllerian hormone in prepubescent and adolescent girls. Fertil Steril 2016. [DOI: 10.1016/j.fertnstert.2016.07.236] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
19
|
Houghton LC, Ester WA, Lumey LH, Michels KB, Wei Y, Cohn BA, Susser E, Terry MB. Maternal weight gain in excess of pregnancy guidelines is related to daughters being overweight 40 years later. Am J Obstet Gynecol 2016; 215:246.e1-246.e8. [PMID: 26901274 DOI: 10.1016/j.ajog.2016.02.034] [Citation(s) in RCA: 30] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/04/2015] [Revised: 02/03/2016] [Accepted: 02/13/2016] [Indexed: 11/29/2022]
Abstract
BACKGROUND Exceeding the Institute of Medicine guidelines for pregnancy weight gain increases childhood and adolescent obesity. However, it is unknown if these effects extend to midlife. OBJECTIVE We sought to determine if exceeding the Institute of Medicine guidelines for pregnancy weight gain increases risk of overweight/obesity in daughters 40 years later. STUDY DESIGN This cohort study is based on adult offspring in the Child Health and Development Studies and the Collaborative Perinatal Project pregnancy cohorts originally enrolled in the 1960s. In 2005 through 2008, 1035 daughters in their 40s were recruited to the Early Determinants of Mammographic Density study. We classified maternal pregnancy weight gain as greater than vs less than or equal to the 2009 clinical guidelines. We used logistic regression to compare the odds ratios of daughters being overweight/obese (body mass index [BMI] ≥25) at a mean age of 44 years between mothers who did not gain or gained more than pregnancy weight gain guidelines, accounting for maternal prepregnant BMI, and daughter body size at birth and childhood. We also examined potential family related confounding through a comparison of sisters using generalized estimating equations, clustered on sibling units and adjusted for maternal age and race. RESULTS Mothers who exceeded guidelines for weight gain in pregnancy were more likely to have daughters who were overweight/obese in their 40s (odds ratio [OR], 3.4; 95% confidence interval {CI}, 2.0-5.7). This magnitude of association translates to a relative risk (RR) increase of 50% (RR = 1.5; 95% CI, 1.3-1.6). The association was of the same magnitude when examining only the siblings whose mother exceeded guidelines in 1 pregnancy and did not exceed the guidelines in the other pregnancy. The association was stronger with increasing maternal prepregnancy BMI (P trend < .001). Compared to mothers with BMI <25 who did not exceed guidelines, the relative risks (RR) for having an overweight/obese adult daughter were 1.3 (95% CI, 1.1-1.7), 1.7 (95% CI, 1.4-2.1) and 1.8 (95% CI, 1.5-2.1), respectively, if mothers exceeded guidelines and their prepregnancy BMI was <25, overweight (BMI 25-<30), or obese (BMI >30). This pattern held irrespective of daughters' weight status at birth, at age 4 years, or at age 20 years. CONCLUSION Our findings support that obesity prevention before pregnancy and strategies to maintain weight gain during pregnancy within the IOM guidelines might reduce the risk of being overweight in midlife for the offspring.
Collapse
Affiliation(s)
- L C Houghton
- Department of Epidemiology, Columbia University, Mailman School of Public Health, 722W 168th Street, New York, NY 10032, USA
| | - W A Ester
- Department of Epidemiology, Columbia University, Mailman School of Public Health, 722W 168th Street, New York, NY 10032, USA
- Parnassia Psychiatric Institute, Kiwistraat 43, 2552 DH, The Hague, The Netherlands
| | - L H Lumey
- Department of Epidemiology, Columbia University, Mailman School of Public Health, 722W 168th Street, New York, NY 10032, USA
- Herbert Irving Comprehensive Cancer Center, Columbia Medical Center, New York, NY, USA
| | - K B Michels
- Obstetrics, and Gynecology Epidemiology Center, Department of Obstetrics, Gynecology and Reproductive Biology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
- Department of Epidemiology, Harvard School of Public Health, Boston, MA, USA
- Institute for Prevention and Cancer Epidemiology, University Medical Center Freiburg, University of Freiburg, Germany
| | - Y Wei
- Department of Biostatistics, Columbia University, Mailman School of Public Health, Street, New York, NY 10032, USA
| | - B A Cohn
- The Center for Research on Women and Children's Health, The Child Health and Development Studies, Public Health Institute, Berkeley, CA, USA
| | - E Susser
- Department of Epidemiology, Columbia University, Mailman School of Public Health, 722W 168th Street, New York, NY 10032, USA
- New York State Psychiatric Institute, New York, NY, USA
| | - M B Terry
- Department of Epidemiology, Columbia University, Mailman School of Public Health, 722W 168th Street, New York, NY 10032, USA
- Herbert Irving Comprehensive Cancer Center, Columbia Medical Center, New York, NY, USA
| |
Collapse
|
20
|
White AJ, Chen J, McCullough LE, Xu X, Cho YH, Conway K, Beyea J, Stellman SD, Steck SE, Mordukhovich I, Eng SM, Terry MB, Engel LS, Hatch M, Neugut AI, Hibshoosh H, Santella RM, Gammon MD. Abstract P1-08-04: Sources of polycyclic aromatic hydrocarbons associated with gene-specific promoter methylation in women with breast cancer. Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-p1-08-04] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Tobacco smoke, diet, and indoor and outdoor air pollution, all major sources of polycyclic aromatic hydrocarbons (PAHs), have been associated with breast cancer incidence. Aberrant methylation may be an early event in carcinogenesis, but whether PAHs influence the epigenome is unclear. Few studies have evaluated whether PAHs are associated with methylation, particularly in breast tumors where methylation changes are particularly relevant. In a population-based case-control study, we measured promoter methylation of 13 breast cancer-related genes in breast tumor tissue (n=765-851 cases) and global methylation in peripheral blood (1,055 cases/1,101 controls). PAH sources (current active smoking, residential environmental tobacco smoke (ETS), vehicular traffic, synthetic log burning, and grilled/smoked meat intake) were evaluated separately. Logistic regression was used to estimate adjusted odds ratios (ORs) and 95% confidence intervals (CIs). When comparing methylated versus unmethylated genes, synthetic log use was associated with increased ORs for CDH1 (OR=2.28, 95%CI=1.07-4.83), HIN1 (OR=2.11, 95%CI=1.32-3.38) and RARβ methylation (OR=1.82, 95%CI=1.18-2.83) and decreased ORs for BRCA1 methylation (OR=0.44, 95%CI=0.30-0.65). Residential ETS was associated with decreased ORs for ESR1 (OR=0.74, 95%CI=0.56-0.99) and CCND2 methylation (OR=0.65, 95%CI=0.44-0.96). Current smoking and vehicular traffic were associated with decreased ORs for DAPK (OR=0.53, 95%CI=0.28-0.99) and increased ORs for TWIST1 methylation (OR=2.79, 95%CI=1.24-6.30), respectively. In controls, synthetic log use was inversely associated with LINE-1 methylation (OR=0.60, 95%CI=0.42-0.87). PAH sources were associated with hypo- and hypermethylation at multiple promoter regions in breast tumors and LINE-1 hypomethylation in blood of controls. Methylation may be a potential biologic mechanism for the association between PAHs and breast cancer incidence.
Citation Format: White AJ, Chen J, McCullough LE, Xu X, Cho YH, Conway K, Beyea J, Stellman SD, Steck SE, Mordukhovich I, Eng SM, Terry MB, Engel LS, Hatch M, Neugut AI, Hibshoosh H, Santella RM, Gammon MD. Sources of polycyclic aromatic hydrocarbons associated with gene-specific promoter methylation in women with breast cancer. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P1-08-04.
Collapse
Affiliation(s)
- AJ White
- University of North Carolina at Chapel Hill; Ichan School of Medicine at Mt. Sinai; Roche Product Development in Asia-Pacific; University of Montana; Consulting in the Public Interest; Columbia University; University of South Carolina; National Cancer Institute
| | - J Chen
- University of North Carolina at Chapel Hill; Ichan School of Medicine at Mt. Sinai; Roche Product Development in Asia-Pacific; University of Montana; Consulting in the Public Interest; Columbia University; University of South Carolina; National Cancer Institute
| | - LE McCullough
- University of North Carolina at Chapel Hill; Ichan School of Medicine at Mt. Sinai; Roche Product Development in Asia-Pacific; University of Montana; Consulting in the Public Interest; Columbia University; University of South Carolina; National Cancer Institute
| | - X Xu
- University of North Carolina at Chapel Hill; Ichan School of Medicine at Mt. Sinai; Roche Product Development in Asia-Pacific; University of Montana; Consulting in the Public Interest; Columbia University; University of South Carolina; National Cancer Institute
| | - YH Cho
- University of North Carolina at Chapel Hill; Ichan School of Medicine at Mt. Sinai; Roche Product Development in Asia-Pacific; University of Montana; Consulting in the Public Interest; Columbia University; University of South Carolina; National Cancer Institute
| | - K Conway
- University of North Carolina at Chapel Hill; Ichan School of Medicine at Mt. Sinai; Roche Product Development in Asia-Pacific; University of Montana; Consulting in the Public Interest; Columbia University; University of South Carolina; National Cancer Institute
| | - J Beyea
- University of North Carolina at Chapel Hill; Ichan School of Medicine at Mt. Sinai; Roche Product Development in Asia-Pacific; University of Montana; Consulting in the Public Interest; Columbia University; University of South Carolina; National Cancer Institute
| | - SD Stellman
- University of North Carolina at Chapel Hill; Ichan School of Medicine at Mt. Sinai; Roche Product Development in Asia-Pacific; University of Montana; Consulting in the Public Interest; Columbia University; University of South Carolina; National Cancer Institute
| | - SE Steck
- University of North Carolina at Chapel Hill; Ichan School of Medicine at Mt. Sinai; Roche Product Development in Asia-Pacific; University of Montana; Consulting in the Public Interest; Columbia University; University of South Carolina; National Cancer Institute
| | - I Mordukhovich
- University of North Carolina at Chapel Hill; Ichan School of Medicine at Mt. Sinai; Roche Product Development in Asia-Pacific; University of Montana; Consulting in the Public Interest; Columbia University; University of South Carolina; National Cancer Institute
| | - SM Eng
- University of North Carolina at Chapel Hill; Ichan School of Medicine at Mt. Sinai; Roche Product Development in Asia-Pacific; University of Montana; Consulting in the Public Interest; Columbia University; University of South Carolina; National Cancer Institute
| | - MB Terry
- University of North Carolina at Chapel Hill; Ichan School of Medicine at Mt. Sinai; Roche Product Development in Asia-Pacific; University of Montana; Consulting in the Public Interest; Columbia University; University of South Carolina; National Cancer Institute
| | - LS Engel
- University of North Carolina at Chapel Hill; Ichan School of Medicine at Mt. Sinai; Roche Product Development in Asia-Pacific; University of Montana; Consulting in the Public Interest; Columbia University; University of South Carolina; National Cancer Institute
| | - M Hatch
- University of North Carolina at Chapel Hill; Ichan School of Medicine at Mt. Sinai; Roche Product Development in Asia-Pacific; University of Montana; Consulting in the Public Interest; Columbia University; University of South Carolina; National Cancer Institute
| | - AI Neugut
- University of North Carolina at Chapel Hill; Ichan School of Medicine at Mt. Sinai; Roche Product Development in Asia-Pacific; University of Montana; Consulting in the Public Interest; Columbia University; University of South Carolina; National Cancer Institute
| | - H Hibshoosh
- University of North Carolina at Chapel Hill; Ichan School of Medicine at Mt. Sinai; Roche Product Development in Asia-Pacific; University of Montana; Consulting in the Public Interest; Columbia University; University of South Carolina; National Cancer Institute
| | - RM Santella
- University of North Carolina at Chapel Hill; Ichan School of Medicine at Mt. Sinai; Roche Product Development in Asia-Pacific; University of Montana; Consulting in the Public Interest; Columbia University; University of South Carolina; National Cancer Institute
| | - MD Gammon
- University of North Carolina at Chapel Hill; Ichan School of Medicine at Mt. Sinai; Roche Product Development in Asia-Pacific; University of Montana; Consulting in the Public Interest; Columbia University; University of South Carolina; National Cancer Institute
| |
Collapse
|
21
|
Leong MJ, Edgar I, Terry M. Penetrating abdominal injury: UK military experience from the Afghanistan conflict. J R Nav Med Serv 2016; 102:90-94. [PMID: 29894136] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/08/2023]
Abstract
AIMS To identify the prevalence, injury patterns and mortality of penetrating abdominal injury in patients treated at the UK Role 3 Medical Treatment Facility (MTF) in Camp Bastion, Afghanistan. METHODS All patients with a penetrating abdominal injury were identified from the UK Joint Theatre Trauma Registry (JTTR). Demographics, predicted survival and observed mortality were compared. Sub-group analyses of UK military patients were conducted, comparing changes in survival as the campaign progressed and identifying the anatomical distribution of abdominal injuries. RESULTS Between June 2006 and June 2013, 1331 of the 8558 (16%) patients recorded on the JTTR had a penetrating abdominal injury; 393 were UK military, of whom 175 (45%) survived. 71% of UK military fatalities had the maximum New Injury Severity Score (NISS) of 75 compared to 4.6% of UK military survivors. The survival rate of UK military patients increased in the later stages of the campaign. Fatal injury in UK military patients was associated with significant vascular or hepatic injuries. CONCLUSIONS This study has defined the epidemiology of penetrating abdominal injury in a modern conflict. Continued training and further research into injury prevention and management will help to ensure that the improved outcomes observed in Afghanistan continue on future operations.
Collapse
|
22
|
Tehranifar P, Protacio A, Akinyemiju TF, Schmitt K, Desperito E, Terry MB. Acculturation and Ethnic Variations in Breast Cancer Risk Factors, Gail Model Risk Estimates and Mammographic Breast Density. Cancer Epidemiol Biomarkers Prev 2015. [DOI: 10.1158/1055-9965.epi-15-0103] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
Abstract
Breast cancer (BC) incidence varies across countries and across US ethnic groups. US Immigrants often exhibit an intermediate level of risk between those observed in their birth country and in the US. This transition of risk may partly be explained by uptake of risk factors associated with acculturation. Investigating whether immigration and acculturation risk patterns are similarly reflected in disease biomarkers can provide insight into mechanisms underlying the transition of risk. We examined differences in the distribution of BC risk factors, absolute risk estimates and mammographic density by ethnicity and acculturation. We used data from 366 women recruited from an urban mammography clinic (ages 40–64 years) to compare BC risk factors and Gail model risk estimates across US-born white, US-born African American [AA], US-born Hispanic and foreign-born Hispanic women. We used linear regression models to examine the associations of immigration and acculturation indicators (e.g., generational status, age and life stage at immigration, language use) with percent density and dense breast area, measured from mammograms. Differences in BC risk factors were mostly observed for ethnic groups, with white women having higher reproductive and lifestyle risk profiles (e.g., lower parity, older age at first birth, higher alcohol intake), Hispanics having shorter height and AAs having larger body mass index (BMI) and waist circumference. The average lifetime and 5-year Gail estimates were highest in whites (11.4% & 1.4%), intermediate in AAs (7.2% & 1.0%) and lowest in Hispanics (6.9% & 0.7% in US-born and 6.6% & 0.8% in foreign-born). After adjusting for age, BMI and parity, lower linguistic acculturation, shorter residence in the US, and later age at immigration were associated with lower percent density (all p values for trend across acculturation levels <0.05); e.g., monolingual Spanish and bilingual speakers respectively had on average 5.6% (95% CI, −10.0–−1.3) and 3.8% (95% CI, −8.1–0.4) lower percent density than monolingual English speakers. Similar but more modest associations were observed for dense area. The increase in BC risk after immigration to the US and subsequent acculturation may operate via influences on mammographic density in Hispanic women.
Collapse
|
23
|
Crew KD, Xiao T, Thomas PS, Terry MB, Maurer M, Kalinsky K, Feldman S, Brafman L, Refice SR, Hershman DL. Safety, Feasibility, and Biomarker Effects of High-Dose Vitamin D Supplementation Among Women at High Risk for Breast Cancer. ACTA ACUST UNITED AC 2015; 2015:1-16. [PMID: 28480224 PMCID: PMC5415303 DOI: 10.19070/2326-3350-si01001] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
Abstract
Vitamin D deficiency is a potentially modifiable risk factor that may be targeted for breast cancer prevention. We examined the safety, feasibility, and biomarker effects of high-dose vitamin D among women at high risk for breast cancer. Forty high-risk women, defined as a 5-year breast cancer risk ≥1.67% per the Gail model, lobular or ductal carcinoma in situ, were assigned to a 1-year intervention of vitamin D3 20,000 IU or 30,000 IU weekly. Participants were monitored for toxicity every 3 months, underwent serial blood draws at baseline, 6 and 12 months, and a digital mammogram at baseline and 12 months. Biomarker endpoints included serum 25-hydroxyvitamin D [25(OH)D], 1,25-dihydroxyvitamin D [1,25(OH)2D], parathyroid hormone (PTH), insulin-like growth factor (IGF-1), IGF binding protein (IGFBP-3), and mammographic density (MD) using Cumulus software. From November 2007 to January 2011, we enrolled 40 women; 37 were evaluable at 6 months and 30 at 12 months. One patient was taken off study for hypercalciuria; otherwise, the intervention was well tolerated. From baseline to 12 months, mean serum 25(OH)D and 1,25(OH)2D rose from 20.0 to 46.9 ng/ml and 69.7 to 98.1 pg/ml, respectively (p<0.01). Serum PTH decreased by 12% at 6 months and IGF-1/IGFBP-3 ratio decreased by 4.3% at 12 months (p<0.05). There was no significant change in MD regardless of menopausal status or dose level. We demonstrated that 1 year of high-dose vitamin D3 was associated with a significant increase in circulating vitamin D levels and favorable effects on IGF signaling, but no significant change in MD.
Collapse
Affiliation(s)
- K D Crew
- Department of Medicine, College of Physicians and Surgeons, Columbia University, New York, NY, USA.,Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY, USA.,Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY, USA
| | - T Xiao
- Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY, USA
| | - P S Thomas
- Department of Clinical Cancer Prevention, MD Anderson Cancer Center, Houston, TX, USA
| | - M B Terry
- Department of Medicine, College of Physicians and Surgeons, Columbia University, New York, NY, USA.,Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY, USA
| | - M Maurer
- Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY, USA.,Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY, USA
| | - K Kalinsky
- Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY, USA.,Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY, USA
| | - S Feldman
- Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY, USA.,Department of Surgery, College of Physicians and Surgeons, Columbia University, New York, NY, USA
| | - L Brafman
- Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY, USA
| | - S R Refice
- Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY, USA
| | - D L Hershman
- Department of Medicine, College of Physicians and Surgeons, Columbia University, New York, NY, USA.,Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY, USA.,Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY, USA
| |
Collapse
|
24
|
Work ME, John EM, Andrulis IL, Knight JA, Liao Y, Mulligan AM, Southey MC, Giles GG, Dite GS, Apicella C, Hibshoosh H, Hopper JL, Terry MB. Reproductive risk factors and oestrogen/progesterone receptor-negative breast cancer in the Breast Cancer Family Registry. Br J Cancer 2014; 110:1367-77. [PMID: 24548865 PMCID: PMC3950851 DOI: 10.1038/bjc.2013.807] [Citation(s) in RCA: 41] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/01/2013] [Revised: 12/03/2013] [Accepted: 12/04/2013] [Indexed: 12/13/2022] Open
Abstract
Background: Oestrogen receptor (ER)- and progesterone receptor (PR)-negative (ER−PR−) breast cancer is associated with poorer prognosis compared with other breast cancer subtypes. High parity has been associated with an increased risk of ER−PR− cancer, but emerging evidence suggests that breastfeeding may reduce this risk. Whether this potential breastfeeding benefit extends to women at high risk of breast cancer remains critical to understand for prevention. Methods: Using population-based ascertained cases (n=4011) and controls (2997) from the Breast Cancer Family Registry, we examined reproductive risk factors in relation to ER and PR status. Results: High parity (⩾3 live births) without breastfeeding was positively associated only with ER−PR− tumours (odds ratio (OR)=1.57, 95% confidence interval (CI), 1.10–2.24); there was no association with parity in women who breastfed (OR=0.93, 95% CI 0.71–1.22). Across all race/ethnicities, associations for ER−PR− cancer were higher among women who did not breastfeed than among women who did. Oral contraceptive (OC) use before 1975 was associated with an increased risk of ER−PR− cancer only (OR=1.32, 95% CI 1.04–1.67). For women who began OC use in 1975 or later there was no increased risk. Conclusions: Our findings support that there are modifiable factors for ER−PR− breast cancer and that breastfeeding in particular may mitigate the increased risk of ER−PR− cancers seen from multiparity.
Collapse
Affiliation(s)
- M E Work
- Department of Epidemiology, Mailman School of Public Health, Columbia University, 722 West 168th Street, New York, NY 10032, USA
| | - E M John
- 1] Cancer Prevention Institute of California, Fremont, CA 94538, USA [2] Division of Epidemiology, Department of Health Research and Policy, and Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA 94305-5101, USA
| | - I L Andrulis
- Department of Molecular Genetics, Samuel Lunenfeld Research Institute, Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada M5G 1X5
| | - J A Knight
- 1] Department of Molecular Genetics, Samuel Lunenfeld Research Institute, Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada M5G 1X5 [2] Division of Epidemiology, Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada M5T 3M7
| | - Y Liao
- Department of Epidemiology, Mailman School of Public Health, Columbia University, 722 West 168th Street, New York, NY 10032, USA
| | - A M Mulligan
- 1] Laboratory Medicine Program, University Health Network, Toronto, Ontario, Canada M5G 1X5 [2] Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada M5G 1X5
| | - M C Southey
- Department of Pathology, The University of Melbourne, Melbourne, VIC 3010, Australia
| | - G G Giles
- 1] Cancer Epidemiology Centre, Cancer Council Victoria, Carlton, VIC 3053, Australia [2] Centre for Molecular, Environmental, Genetic and Analytic Epidemiology, University of Melbourne, Melbourne, VIC 3010, Australia
| | - G S Dite
- Centre for Molecular, Environmental, Genetic and Analytic Epidemiology, University of Melbourne, Melbourne, VIC 3010, Australia
| | - C Apicella
- Centre for Molecular, Environmental, Genetic and Analytic Epidemiology, University of Melbourne, Melbourne, VIC 3010, Australia
| | - H Hibshoosh
- Department of Epidemiology and Institute of Health and Environment, School of Public Health, Seoul National University, 110-799 Seoul, Korea
| | - J L Hopper
- 1] Centre for Molecular, Environmental, Genetic and Analytic Epidemiology, University of Melbourne, Melbourne, VIC 3010, Australia [2] Department of Epidemiology and Institute of Health and Environment, School of Public Health, Seoul National University, 110-799 Seoul, Korea
| | - M B Terry
- 1] Department of Epidemiology, Mailman School of Public Health, Columbia University, 722 West 168th Street, New York, NY 10032, USA [2] Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY 10032, USA
| |
Collapse
|
25
|
Chehayeb Makarem D, Reimers L, Greenlee H, Terry MB, Whiffen A, Crew K. Abstract P4-09-01: Impact of adherence to guidelines on nutrition and physical activity for breast cancer prevention in high-risk women. Cancer Res 2013. [DOI: 10.1158/0008-5472.sabcs13-p4-09-01] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Women who are at high-risk for breast cancer based upon their family history or benign breast disease are candidates for chemoprevention and other risk reduction strategies. Breast cancer risk factors such as obesity, lack of physical activity and alcohol consumption represent important modifiable behaviors to target for prevention due to their high prevalence and negative impact on multiple chronic diseases. We evaluated the effect of adherence to cancer prevention guidelines for body mass index (BMI), alcohol consumption, physical activity and diet on breast cancer development and predictors of adherence to these guidelines among high-risk women.
Methods: From 1991-2011, 2674 participants were enrolled to a prospective cohort study called the Women at Risk registry at the Columbia University Medical Center (CUMC) breast clinic and 1600 evaluable patients had complete data and at least one follow-up visit. The study population included women who met one or more of the following criteria: 1) one or more first-degree relatives with premenopausal breast cancer; 2) two or more first-degree relatives with postmenopausal breast cancer; 3) known BRCA1 or BRCA2 deleterious mutation carrier; 4) a biopsy-proven history of atypical hyperplasia or lobular carcinoma in situ. Women completed a baseline epidemiologic questionnaire and were followed for an average of 4.5 years during routine clinic visits with breast surgery. Using unconditional logistic regression, we examined the association between adherence to the following lifestyle factors and breast cancer risk among 90 prospectively-ascertained breast cancer cases and 1510 unaffected controls: 1) BMI of 18.5-25 kg/m2, 2) alcohol consumption of <1 serving per week, 3) eating a strict low-fat or vegetarian diet, 4) engaging in moderate physical activity daily. A total adherence score (range, 0-8) for the 4 health behaviors was calculated, where 0 = non-adherent, 1 = partially adherent, 2 = fully adherent. Linear logistic regression was conducted to assess the association between sociodemographics and known breast cancer risk factors with adherence score.
Results: Median age: 47 years; race/ethnicity, White/Hispanic/Black/Asian/other/unknown (%): 76/7/4/2/5/6; first-degree family history of breast cancer: 57%; benign breast disease: 60%; BMI of 18.5-25 kg/m2: 66%; consumption of <1 serving of alcohol/week: 59%; strict low-fat/vegetarian diet: 20%; daily exercise: 20%. BMI greater than 25 kg/m2 was associated with a higher risk of developing breast cancer compared to those with a BMI less than or equal to 25 kg/m2 (RR = 2.69, 95% CI = 1.21-5.94), even after adjustment for diet and exercise. In multivariate analysis, older age (b = -0.013, 95% CI = -0.0257, -0.0003) and non-white race (β = -0.378, 95% CI = -0.761, 0.004) were associated with a lower adherence score for health behaviors.
Conclusion: Among high-risk women, being overweight or obese was associated with a 2.7-fold increased breast cancer risk compared to those with a lean body weight. Older women and non-white women were less likely to adhere to cancer prevention guidelines. We have identified a potentially modifiable breast cancer risk factor and vulnerable populations to target for breast cancer prevention.
Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr P4-09-01.
Collapse
Affiliation(s)
| | - L Reimers
- Columbia University Medical Center, New York, NY
| | - H Greenlee
- Columbia University Medical Center, New York, NY
| | - MB Terry
- Columbia University Medical Center, New York, NY
| | - A Whiffen
- Columbia University Medical Center, New York, NY
| | - K Crew
- Columbia University Medical Center, New York, NY
| |
Collapse
|
26
|
Sivasubramanian PS, Reimers LL, Greenlee H, Terry MB, Hershman D, Maurer M, Kalinsky K, Awad D, Xiao T, Sandoval R, Alvarez M, Quirarte A, Campbell J, Crew KD. Abstract P5-13-01: Uptake of breast cancer chemoprevention among high-risk women and those with ductal carcinoma in situ. Cancer Res 2013. [DOI: 10.1158/0008-5472.sabcs13-p5-13-01] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Chemoprevention with antiestrogens, such as tamoxifen, raloxifene, and aromatase inhibitors (AIs), reduces breast cancer incidence in high-risk women. However, uptake has been poor in the prevention setting. We examined demographic and clinical factors that influenced chemoprevention uptake in women with an elevated Gail risk score (≥1.67%), lobular/ductal carcinoma in situ (LCIS/DCIS), and/or BRCA mutation carriers.
Methods: We enrolled women prospectively without a diagnosis of invasive breast cancer, who were seen for an initial consultation by breast surgery or medical oncology at Columbia University Medical Center. Eligibility for chemoprevention included a 5-year Gail risk ≥1.67%, LCIS, known BRCA1 or BRCA2 mutation, or hormone receptor (HR)-positive DCIS. Demographic and risk factor data were collected from a self-administered baseline questionnaire and clinical data from medical chart review, including prior/current chemoprevention, type of antiestrogen, duration of use, and toxicities. Differences in distribution of risk factors between women who ever took chemoprevention and those who did not were examined using chi-square statistics or Fisher's exact test. We used log-binomial regression models to estimate relative risks (RRs) and 95% confidence intervals (95% CI) using chemoprevention uptake as the dependent variable. A subset of high-risk women completed questionnaires assessing their attitudes towards chemoprevention and perceived risks/benefits.
Results: Among 412 women enrolled between March 2007 and April 2013, 316 (77%) were eligible for chemoprevention. Main reasons for ineligibility included 5-year Gail risk <1.67% (40%), age <35 (24%), HR-negative DCIS (17%), opting for bilateral mastectomies (11%), and medical contraindications (8%). Among those eligible for chemoprevention, median age 53 (26-88); White/Hispanic/Black/Asian/other (%): 55/29/8/7/1; risk category, 5-year Gail risk ≥1.67%/LCIS/DCIS/BRCA mutation (%): 36/22/40/2. Overall, 162 (51%) women started an antiestrogen (72% for DCIS and 37% among high-risk women), including 114 on tamoxifen, 40 on raloxifene, and 11 on an AI. Early discontinuation occurred in 27 (18%) women, but 7 switched to a different antiestrogen. In univariable analysis, postmenopausal status and medical oncology referral were associated with higher chemoprevention uptake. In multivariable analysis, only higher risk was a significant predictor of chemoprevention uptake. Among the subset of women who completed additional questionnaires on attitudes towards chemoprevention, they reported that the most important factors in chemoprevention decision-making included their healthcare provider (50%), results of chemoprevention studies (44%), and knowledge about others’ experience with chemoprevention (44%). The majority (69%) were concerned about side effects, specifically blood clots with tamoxifen and raloxifene and bone fractures with AIs.
Conclusions: In high-risk women seen at an academic breast center, chemoprevention uptake was relatively high compared to the published literature. Further research is needed to determine how the risks and benefits of chemoprevention are best communicated to women to enhance informed decision-making and increase uptake of chemoprevention strategies.
Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr P5-13-01.
Collapse
Affiliation(s)
| | | | | | - MB Terry
- Columbia University, New York, NY
| | | | - M Maurer
- Columbia University, New York, NY
| | | | - D Awad
- Columbia University, New York, NY
| | - T Xiao
- Columbia University, New York, NY
| | | | | | | | | | - KD Crew
- Columbia University, New York, NY
| |
Collapse
|
27
|
Zhang X, Cruz FD, Terry M, Remotti F, Matushansky I. Terminal differentiation and loss of tumorigenicity of human cancers via pluripotency-based reprogramming. Oncogene 2012; 32:2249-60, 2260.e1-21. [PMID: 22777357 PMCID: PMC3470785 DOI: 10.1038/onc.2012.237] [Citation(s) in RCA: 97] [Impact Index Per Article: 8.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Abstract
Pluripotent cells can be derived from various types of somatic cells by nuclear reprogramming using defined transcription factors. It is, however, unclear whether human cancer cells can be similarly reprogrammed and subsequently terminally differentiated with abrogation of tumorigenicity. Here, using sarcomas we show that human-derived complex karyotype solid tumors: (1) can be reprogrammed into a pluripotent-like state as defined by all in vitro criteria used to define pluripotent stem cells generated from somatic cells; (2) can be terminally differentiated into mature connective tissue and red blood cells; and (3) terminal differentiation is accompanied with loss of both proliferation and tumorigenicity. We go on to perform the first global DNA promoter methylation and gene expression analyses comparing human cancers to their reprogrammed counterparts and report that reprogramming/differentiation results in significant epigenetic remodeling of oncogenes and tumor suppressors, while not significantly altering the differentiation status of the reprogrammed cancer cells, in essence dedifferentiating them to a state slightly before the mesenchymal stem cell differentiation stage. Our data demonstrate that direct nuclear reprogramming can restore terminal differentiation potential to human-derived cancer cells, with simultaneous loss of tumorigenicity, without the need to revert to an embryonic state. We anticipate that our models would serve as a starting point to more fully assess how nuclear reprogramming overcomes the multitude of genetic and epigenetic aberrancies inherent in human cancers to restore normal terminal differentiation pathways. Finally, these findings suggest that nuclear reprogramming may be a broadly applicable therapeutic strategy for the treatment of cancer.
Collapse
Affiliation(s)
- X Zhang
- Division of Medical Oncology, Department of Medicine, Columbia University Medical Center, New York, NY 10032, USA
| | | | | | | | | |
Collapse
|
28
|
Phillips KA, Milne RL, Rookus MA, Goldgar D, Friedlander M, McLachlan SA, Buys S, Antoniou AC, Birch K, Terry MB, Easton DF, Weideman P, Daly M, Andrieu N, John EM, Hooning MJ, Andrulis IL, Caldes T, Olsson H, Hopper JL. Association of tamoxifen use and reduced risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. Hered Cancer Clin Pract 2012. [PMCID: PMC3395384 DOI: 10.1186/1897-4287-10-s2-a11] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022] Open
|
29
|
Reimers LL, Campbell J, Hershman D, Greenlee H, Terry MB, Maurer M, Kalinsky K, Jayasena R, Sandoval R, Alvarez M, Crew KD. P4-11-06: Uptake of Selective Estrogen Receptor Modulators and Other Breast Cancer Prevention Strategies among High-Risk Women Seen in a Breast Center. Cancer Res 2011. [DOI: 10.1158/0008-5472.sabcs11-p4-11-06] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Selective estrogen receptor modulators (SERMs), tamoxifen and raloxifene, are FDA-approved for breast cancer (BC) risk reduction. However, uptake has been poor in the prevention setting, partly due to a lack of knowledge in the medical community about BC prevention and public misconceptions about the risks of SERMs. We assessed demographic and clinical factors that influence SERM uptake among high-risk women seen in an academic breast center, where specialized risk counseling is provided by a breast surgeon or medical oncologist.
Methods: Potential subjects included high-risk women seen for an initial consultation by Breast Surgery or Medical Oncology. Eligibility for SERM use included a 5-year Gail risk ≥1.67%, lobular carcinoma in situ (LCIS), BRCA mutation carrier, or estrogen receptor (ER)-positive and/or progesterone receptor (PR)-positive ductal carcinoma in situ (DCIS). Demographic and BC risk factor data was collected from self-administered questionnaires. Clinical data, including prior/current SERM use, was abstracted from medical chart review. Differences in distribution of risk factors, between women who ever took a SERM and those who did not, were examined using chi-square statistics or Fisher's exact test. Multivariable logistic regression models were used to calculate odds ratios (OR) and 95% confidence intervals using SERM use as the dependent variable.
Results: Among 247 high-risk women enrolled between March 2007 and January 2011, median age 51 (17-82); White/Hispanic/Black/Asian (%): 55/32/7/6. 85% of women were undergoing annual mammography, 94% had a breast biopsy, 19% genetic testing, and 71% Medical Oncology referral. Among 181 (73%) women eligible for a SERM, Gail risk ≥1.67%/LCIS/DCIS/BRCA mutation (%): 35/22/39/3; 83 (46%) ever took a SERM, including 62 on tamoxifen and 21 on raloxifene. Early SERM discontinuation was only 7%. In multivariable analysis, significant predictors of SERM uptake included risk category (DCIS vs. Gail risk ≥1.67%/LCIS/BRCA mutation), higher income, higher body mass index (BMI), and referral to Medical Oncology. In terms of this high-risk population meeting American Cancer Society (ACS) behavioral guidelines for cancer prevention, 53% had a BMI <25 kg/m2, 44% consumed ≤1 alcoholic beverage per day, and 10% engaged in ≥4 hours of moderate physical activity per week; only 3.5% met all 3 recommendations.
Conclusions: Among high-risk women seen at a specialized breast center, application of clinical recommendations such as screening mammography, genetic testing, and SERM uptake were relatively high, suggesting that a comprehensive approach to the management of high-risk women is feasible. However, meeting ACS nutrition and physical activity guidelines for cancer prevention was limited, perhaps due to a lack of reimbursable staff to implement these guidelines. Breast cancer risk assessment and available interventions for prevention among high-risk women are underutilized in the U.S. Future studies should focus on the development and delivery of breast cancer prevention strategies.
Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr P4-11-06.
Collapse
Affiliation(s)
- LL Reimers
- 1Columbia University Mailman School of Public Health, New York, NY; Columbia University College of Physicians and Surgeons, New York, NY; Columbia University, New York, NY
| | - J Campbell
- 1Columbia University Mailman School of Public Health, New York, NY; Columbia University College of Physicians and Surgeons, New York, NY; Columbia University, New York, NY
| | - D Hershman
- 1Columbia University Mailman School of Public Health, New York, NY; Columbia University College of Physicians and Surgeons, New York, NY; Columbia University, New York, NY
| | - H Greenlee
- 1Columbia University Mailman School of Public Health, New York, NY; Columbia University College of Physicians and Surgeons, New York, NY; Columbia University, New York, NY
| | - MB Terry
- 1Columbia University Mailman School of Public Health, New York, NY; Columbia University College of Physicians and Surgeons, New York, NY; Columbia University, New York, NY
| | - M Maurer
- 1Columbia University Mailman School of Public Health, New York, NY; Columbia University College of Physicians and Surgeons, New York, NY; Columbia University, New York, NY
| | - K Kalinsky
- 1Columbia University Mailman School of Public Health, New York, NY; Columbia University College of Physicians and Surgeons, New York, NY; Columbia University, New York, NY
| | - R Jayasena
- 1Columbia University Mailman School of Public Health, New York, NY; Columbia University College of Physicians and Surgeons, New York, NY; Columbia University, New York, NY
| | - R Sandoval
- 1Columbia University Mailman School of Public Health, New York, NY; Columbia University College of Physicians and Surgeons, New York, NY; Columbia University, New York, NY
| | - M Alvarez
- 1Columbia University Mailman School of Public Health, New York, NY; Columbia University College of Physicians and Surgeons, New York, NY; Columbia University, New York, NY
| | - KD Crew
- 1Columbia University Mailman School of Public Health, New York, NY; Columbia University College of Physicians and Surgeons, New York, NY; Columbia University, New York, NY
| |
Collapse
|
30
|
|
31
|
Work ME, John EM, Andrulis IL, Hopper JL, Liao Y, Hibshoosh H, Terry MB. Oral Contraceptive Use and Parity Associations with Uncommon Breast Cancer Histologies in the Breast Cancer Family Registry: the Role of Family History. Cancer Epidemiol Biomarkers Prev 2011. [DOI: 10.1158/1055-9965.epi-11-0084] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
Abstract
Purpose: The effect of parity and oral contraceptive (OC) use on breast cancer risk differs by cancer subtype as defined by histology. Family history of breast cancer impacts decisions regarding both parity and oral contraceptive use; it is unknown whether reproductive risk factors are related to uncommon histologies in women with and without a strong family history.
Methods: Using population-based data from the Breast Cancer Family Registry, we conducted analyses using unordered polytomous regression to determine the role of family history in associations between parity, OC use, and breast cancer histologic subtype, among 3,260 cases and 2,997 controls. Histologic types examined included ductal and lobular as well as the uncommon histologies of mucinous, tubular, and medullary cancer.
Results: Twenty-eight percent of cases and 9% of controls had a family history (defined as at least 1 first-degree relative with breast cancer). Cases with and without family history were similar in regards to OC use (75% and 73%, respectively were ever-users) and parity (2.08 children in cases with family history, 2.10 in cases without). In a multivariable model, when compared with controls, OC use was inversely associated with tumors of mucinous histology (OR = 0.43, 95% CI 0.23–0.79 for use ≥5 years vs. never use). There was a stronger inverse association with OC use and the mucinous subtype among those without a family history (OR = 0.27, 95% CI 0.13–0.57), and a nonsignificant positive association in those with family history (OR = 2.19, 95% CI 0.40–11.84). High parity (≥3 children) was positively associated with medullary histology (OR = 2.62, 95% CI 1.16–5.91, compared with nulliparity); the association was stronger among women without a family history (OR = 4.31, 95% CI 1.67–11.12), and was not significantly associated among those with a family history (OR = 0.36, 95% CI 0.06–2.29). Parity was inversely associated with the mucinous type (OR = 0.45, 95% CI 0.21–0.96, compared with nulliparity), and this effect remained stable in women with and without family history.
Conclusion: This study suggests that selected reproductive risk factors may only be related to uncommon breast cancer histologies among women without a family history of breast cancer.
Collapse
|
32
|
Flom J, Ferris J, Gonzalez K, Santella R, Terry MB. Prenatal Tobacco Smoke Exposure and Genomewide Methylation in Adulthood. Cancer Epidemiol Biomarkers Prev 2011. [DOI: 10.1158/1055-9965.epi-11-0097] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
Abstract
Genomic DNA demethylation, including demethylation of repetitive elements (which comprise 45% of the human genome), has been linked to increased risk of breast and other cancers. Genomic DNA methylation can be altered prenatally and throughout life and may be a mechanism through which the environment alters disease risk. There is evidence that prenatal tobacco smoke exposure has a persistent impact on genomic DNA methylation; however, no study to date has assessed the association between prenatal smoke exposure and adult repetitive element methylation. We measured repetitive element methylation of Alu, LINE-1, and Sat2 using MethyLight in 92 members of the New York Women's Birth Cohort, a follow-up of former female participants of the New York site of the U.S. National Collaborative Perinatal Project (mean age at blood draw = 43.5, SD = 1.8). Prenatal smoke exposure was reported prospectively. We estimated associations using multivariable linear regression, and used the natural log of Alu, LINE-1, and Sat2 methylation level. Thirty-one (36%) participants were exposed to prenatal smoke. These participants were more likely to smoke at the time of interview (P < 0.01). Prenatal smoke exposure was inversely associated with genomic DNA methylation of Sat2 and Alu, adjusted for age, childhood environmental tobacco smoke exposure (ETS) and adult smoking status (exposed vs. unexposed to prenatal smoke: Sat2: β = −0.20, 95% CI = −0.39, −0.02; Alu: β = −0.09, 95% CI = −0.26, 0.08). In multivariable models, childhood ETS had a positive, borderline significant association with Sat2 methylation (β = 0.17, 95% CI −0.02, 0.37). If replicated in larger studies, these results suggest that prenatal smoke exposure may have a persistent impact on genomic DNA demethylation of Sat2 and Alu in adulthood, and thus may be a pathway through which prenatal smoke exposure impacts adult disease. Results are strengthened by the fact that prenatal smoke exposure data were collected prospectively in the early 1960s, before there was a stigma associated with maternal smoking during pregnancy. These results are consistent with the one study assessing this relation in children. Further studies are needed to confirm this finding and to investigate the underlying biological mechanism.
Collapse
|
33
|
Schrader KA, Masciari S, Boyd N, Salamanca C, Senz J, Saunders DN, Yorida E, Maines-Bandiera S, Kaurah P, Tung N, Robson ME, Ryan PD, Olopade OI, Domchek SM, Ford J, Isaacs C, Brown P, Balmana J, Razzak AR, Miron P, Coffey K, Terry MB, John EM, Andrulis IL, Knight JA, O'Malley FP, Daly M, Bender P, Moore R, Southey MC, Hopper JL, Garber JE, Huntsman DG. Germline mutations in CDH1 are infrequent in women with early-onset or familial lobular breast cancers. J Med Genet 2011; 48:64-8. [PMID: 20921021 PMCID: PMC3003879 DOI: 10.1136/jmg.2010.079814] [Citation(s) in RCA: 66] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
BACKGROUND Germline mutations in CDH1 are associated with hereditary diffuse gastric cancer; lobular breast cancer also occurs excessively in families with such condition. METHOD To determine if CDH1 is a susceptibility gene for lobular breast cancer in women without a family history of diffuse gastric cancer, germline DNA was analysed for the presence of CDH1 mutations in 318 women with lobular breast cancer who were diagnosed before the age of 45 years or had a family history of breast cancer and were not known, or known not, to be carriers of germline mutations in BRCA1 or BRCA2. Cases were ascertained through breast cancer registries and high-risk cancer genetic clinics (Breast Cancer Family Registry, the kConFab and a consortium of breast cancer genetics clinics in the United States and Spain). Additionally, Multiplex Ligation-dependent Probe Amplification was performed for 134 cases to detect large deletions. RESULTS No truncating mutations and no large deletions were detected. Six non-synonymous variants were found in seven families. Four (4/318 or 1.3%) are considered to be potentially pathogenic through in vitro and in silico analysis. CONCLUSION Potentially pathogenic germline CDH1 mutations in women with early-onset or familial lobular breast cancer are at most infrequent.
Collapse
Affiliation(s)
- K A Schrader
- Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, Canada
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
34
|
Wye P, Bowman J, Wiggers J, Baker A, Carr V, Terry M, Knight J, Clancy R. Providing nicotine dependence treatment to psychiatric inpatients: the views of Australian nurse managers. J Psychiatr Ment Health Nurs 2010; 17:319-27. [PMID: 20529182 DOI: 10.1111/j.1365-2850.2009.01524.x] [Citation(s) in RCA: 32] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
The prevalence of smoking in psychiatric settings remains high. This study aims to describe the views of nurse managers in psychiatric inpatient settings regarding the provision of nicotine dependence treatment, and whether there were associations between such views and the provision of nicotine dependence treatment. A cross-sectional survey was mailed to all public psychiatric inpatient units in New South Wales, Australia, for completion by nurse managers. Of the identified 131 service units, 123 completed questionnaires were returned (94%). Patient-related factors were considered to have a high level of influence on the provision of nicotine dependence treatment: patients requesting assistance to quit (58%), patients being receptive to interventions (52%), and patient health improving with quitting (45%). Units where the respondent reported that nicotine dependence treatment was as important as other roles were more likely to provide nicotine dependence treatment compared to units whose respondents did not hold this view (OR = 0.257, d.f. = 1, P < 0.01). While the results indicate strong support for the provision of nicotine dependence treatment, this support appears qualified by perceived patient readiness to quit, suggesting care is provided selectively rather than systematically. Positioning smoking as an addiction requiring treatment within a traditional curative approach may lead to a health service more conducive to the routine provision of nicotine dependence treatment.
Collapse
Affiliation(s)
- P Wye
- Hunter New England Population Health, Tamworth NSW, Australia.
| | | | | | | | | | | | | | | |
Collapse
|
35
|
Osorio A, Milne RL, Pita G, Peterlongo P, Heikkinen T, Simard J, Chenevix-Trench G, Spurdle AB, Beesley J, Chen X, Healey S, Neuhausen SL, Ding YC, Couch FJ, Wang X, Lindor N, Manoukian S, Barile M, Viel A, Tizzoni L, Szabo CI, Foretova L, Zikan M, Claes K, Greene MH, Mai P, Rennert G, Lejbkowicz F, Barnett-Griness O, Andrulis IL, Ozcelik H, Weerasooriya N, Gerdes AM, Thomassen M, Cruger DG, Caligo MA, Friedman E, Kaufman B, Laitman Y, Cohen S, Kontorovich T, Gershoni-Baruch R, Dagan E, Jernström H, Askmalm MS, Arver B, Malmer B, Domchek SM, Nathanson KL, Brunet J, Ramón Y Cajal T, Yannoukakos D, Hamann U, Hogervorst FBL, Verhoef S, Gómez García EB, Wijnen JT, van den Ouweland A, Easton DF, Peock S, Cook M, Oliver CT, Frost D, Luccarini C, Evans DG, Lalloo F, Eeles R, Pichert G, Cook J, Hodgson S, Morrison PJ, Douglas F, Godwin AK, Sinilnikova OM, Barjhoux L, Stoppa-Lyonnet D, Moncoutier V, Giraud S, Cassini C, Olivier-Faivre L, Révillion F, Peyrat JP, Muller D, Fricker JP, Lynch HT, John EM, Buys S, Daly M, Hopper JL, Terry MB, Miron A, Yassin Y, Goldgar D, Singer CF, Gschwantler-Kaulich D, Pfeiler G, Spiess AC, Hansen TVO, Johannsson OT, Kirchhoff T, Offit K, Kosarin K, Piedmonte M, Rodriguez GC, Wakeley K, Boggess JF, Basil J, Schwartz PE, Blank SV, Toland AE, Montagna M, Casella C, Imyanitov EN, Allavena A, Schmutzler RK, Versmold B, Engel C, Meindl A, Ditsch N, Arnold N, Niederacher D, Deissler H, Fiebig B, Varon-Mateeva R, Schaefer D, Froster UG, Caldes T, de la Hoya M, McGuffog L, Antoniou AC, Nevanlinna H, Radice P, Benítez J. Evaluation of a candidate breast cancer associated SNP in ERCC4 as a risk modifier in BRCA1 and BRCA2 mutation carriers. Results from the Consortium of Investigators of Modifiers of BRCA1/BRCA2 (CIMBA). Br J Cancer 2009; 101:2048-54. [PMID: 19920816 PMCID: PMC2795432 DOI: 10.1038/sj.bjc.6605416] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022] Open
Abstract
Background: In this study we aimed to evaluate the role of a SNP in intron 1 of the ERCC4 gene (rs744154), previously reported to be associated with a reduced risk of breast cancer in the general population, as a breast cancer risk modifier in BRCA1 and BRCA2 mutation carriers. Methods: We have genotyped rs744154 in 9408 BRCA1 and 5632 BRCA2 mutation carriers from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA) and assessed its association with breast cancer risk using a retrospective weighted cohort approach. Results: We found no evidence of association with breast cancer risk for BRCA1 (per-allele HR: 0.98, 95% CI: 0.93–1.04, P=0.5) or BRCA2 (per-allele HR: 0.97, 95% CI: 0.89–1.06, P=0.5) mutation carriers. Conclusion: This SNP is not a significant modifier of breast cancer risk for mutation carriers, though weak associations cannot be ruled out.
Collapse
Affiliation(s)
- A Osorio
- Human Genetics Group, Spanish National Cancer Research Centre, C/Melchor Fernández Almagro 3, 28029 Madrid, Spain.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
36
|
Mukherjee SD, Hodgson N, Peter L, Shelley C, Jonathan S, Terry M, Kavita D, Tim W. The impact of preoperative breast magnetic resonance imaging (MRI) on surgical decision-making in young patients with breast cancer. Cancer Res 2009. [DOI: 10.1158/0008-5472.sabcs-4012] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Abstract #4012
Recent data suggests that breast MRI is a more sensitive diagnostic test for detecting invasive breast cancer than mammography or breast ultrasound. Breast MRI may be particularly useful in younger premenopausal women with higher density breast tissue for differentiating between dense fibroglandular breast tissue and breast malignancies. The primary objective of this study was to determine the impact of pre-operative breast MRI on surgical decision-making in young women with breast cancer.
 Methods: A retrospective review of 32 patients with newly diagnosed invasive breast cancer and age ≤ 50 was performed. All patients underwent a physical examination, preoperative mammogram, breast ultrasound, and bilateral breast MRI. Two breast cancer surgeons reviewed the preoperative mammogram report, breast ultrasound report, and physical examination summary for each case and were asked if they would recommend a lumpectomy, quandrantectomy, or mastectomy. A few weeks later, the two surgeons were shown the same information with the breast MRI report and were asked what type of surgery they would now recommend. In each case, MRI was classified by two adjudicators as having affected the surgical outcome in a positive, negative, or neutral fashion. A 'Positive Impact' was defined as the situation where breast MRI detected additional disease that was not found on physical exam, mammogram, or breast ultrasound and led to an appropriate change in surgical management. A 'Negative Impact' was defined as the situation where the breast MRI results led the surgeon to recommend more extensive surgery, with less extensive disease actually found at pathology. 'No Impact' was defined as the situation where MRI findings did not alter surgical recommendations or outcome.
 Results: The median age was 41.5 years. The pathologic diagnosis was invasive ductal carcinoma in 94% (30/32) and invasive lobular carcinoma in 6% (2/32) of cases. For surgeon A, clinical management was altered in 21/32 (66%) of cases, and for surgeon B, management was altered in 13/32 (41%) of cases. The most common change in surgical decision-making after breast MRI was from breast conserving surgery to a mastectomy. Mastectomy rates were similar between both surgeons after breast MRI. After reviewing the pathology results and comparing them with the breast MRI results, it was determined that breast MRI led to a positive outcome in 13/32 cases (41%). Breast MRI led to no change in surgical management in 15/32 (47%) cases and resulted in a negative change in surgical management in 4/32 (13%) cases. Bilateral breast MRI detected a contralateral breast cancer in 2/32 (6%) patients.
 Conclusions: Preoperative breast MRI appears to result in a change in surgical management in a significant proportion of younger women. Further research is needed to determine if this change in surgical decision-making will result in improved local control.
Citation Information: Cancer Res 2009;69(2 Suppl):Abstract nr 4012.
Collapse
Affiliation(s)
- SD Mukherjee
- 1 Oncology, Juravinski Cancer Centre, Hamilton, ON, Canada
| | - N Hodgson
- 1 Oncology, Juravinski Cancer Centre, Hamilton, ON, Canada
| | - L Peter
- 2 Surgery, St. Joseph's Hospital, Hamilton, ON, Canada
| | - C Shelley
- 1 Oncology, Juravinski Cancer Centre, Hamilton, ON, Canada
| | - S Jonathan
- 1 Oncology, Juravinski Cancer Centre, Hamilton, ON, Canada
| | - M Terry
- 1 Oncology, Juravinski Cancer Centre, Hamilton, ON, Canada
| | - D Kavita
- 1 Oncology, Juravinski Cancer Centre, Hamilton, ON, Canada
| | - W Tim
- 1 Oncology, Juravinski Cancer Centre, Hamilton, ON, Canada
| |
Collapse
|
37
|
Holton T, Smith D, Terry M, Madgwick A, Levine T. The effect of lubricant contamination on ThinPrep(Cytyc) cervical cytology liquid-based preparations. Cytopathology 2008; 19:236-43. [DOI: 10.1111/j.1365-2303.2007.00525.x] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
38
|
Schrader K, Masciari S, Boyd N, Senz J, Kaurah P, Terry MB, John E, Andrulis IL, Knight J, O'Malley FP, Daly M, Bender P, Southey MC, Hopper JL, Garber J, Huntsman DG. THE ASSOCIATION OF LOBULAR BREAST CANCER WITH GERMLINE MUTATIONS OF CDH1. CLIN INVEST MED 2008. [DOI: 10.25011/cim.v31i4.4826] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
Background: CDH1 encodes the cell-cell adhesion molecule, E-cadherin, for which loss of expression facilitates the infiltrative and metastatic potential of cancers. Germline mutations in CDH1 are associated with hereditary diffuse gastric cancer (HDGC), and in this setting female carriers have been estimated to have a 39-50% risk of lobular breast cancer (LBC) by age 80 years.
Aim: To determine the frequency of CDH1 germline mutations inindividuals with early-onset LBC or those with LBC and a family history of multiple breast cancers but no gastric cancers.
Methods: Germline DNA analysis of CDH1 in women with LBC, for whom germline BRCA1 and BRCA2 mutations have been excluded, who have been (1) diagnosed before the age of 45 years or (2) diagnosed at any age and have a family history of breast cancer.
Results: Analysis of 194 LBC cases has thus far revealed two novel missense mutations predicted to affect protein function. Functional assays to assess their pathogenicity along with germline analyses of the remaining 200 cases are currently underway. Several unreported silent changes have also been identified and will be measured in a case- control sample to assess whether they are associated with LBC risk.
Conclusion: Germline CDH1 mutations may cause a small proportion of familial and early onset LBC.
Collapse
|
39
|
Perrin MC, Terry MB, Kleinhaus K, Deutsch L, Yanetz R, Tiram E, Calderon R, Friedlander Y, Paltiel O, Harlap S. Gestational diabetes as a risk factor for pancreatic cancer: a prospective cohort study. BMC Med 2007; 5:25. [PMID: 17705823 PMCID: PMC2042496 DOI: 10.1186/1741-7015-5-25] [Citation(s) in RCA: 40] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/09/2006] [Accepted: 08/16/2007] [Indexed: 12/30/2022] Open
Abstract
BACKGROUND Diabetes is known to be associated with cancer of the pancreas, though there is some debate as to whether it is a cause or a consequence of the disease. We investigated the incidence of pancreatic cancer in a cohort of 37926 Israeli women followed for 28-40 years for whom information on diabetes had been collected at the time they gave birth, in 1964-1976, in Jerusalem. There were 54 cases of pancreatic cancer ascertained from the Israel Cancer Registry during follow-up. METHODS We used Cox proportional hazards models to adjust for age at baseline and explore effects of other risk factors, including ethnic groups, preeclampsia, birth order and birth weight of offspring. RESULTS We observed no cases of pancreatic cancer in the women with insulin dependent diabetes; however, there were five cases in the women with gestational diabetes. The interval between the record of diabetes in pregnancy and the diagnosis of pancreatic cancer ranged from 14-35 years. Women with a history of gestational diabetes showed a relative risk of pancreatic cancer of 7.1 (95% confidence interval, 2.8-18.0). CONCLUSION We conclude that gestational diabetes is strongly related to the risk of cancer of the pancreas in women in this population, and that gestational diabetes can precede cancer diagnosis by many years.
Collapse
Affiliation(s)
- MC Perrin
- Department of Psychiatry, School of Medicine, New York University, 550 1st Avenue, New York, NY 10017, USA
- Department of Epidemiology, Mailman School of Public Health, Columbia University, 722 West 168th Street, New York, NY 10032, USA
| | - MB Terry
- Department of Epidemiology, Mailman School of Public Health, Columbia University, 722 West 168th Street, New York, NY 10032, USA
| | - K Kleinhaus
- New York State Psychiatric Institute, 1051 Riverside Avenue, New York, NY 10032, USA
| | - L Deutsch
- Unit of Epidemiology, The Hebrew University-Hadassah School of Public Health, Ein Kerem, Jerusalem, 91120, Israel
| | - R Yanetz
- Unit of Epidemiology, The Hebrew University-Hadassah School of Public Health, Ein Kerem, Jerusalem, 91120, Israel
| | - E Tiram
- Unit of Epidemiology, The Hebrew University-Hadassah School of Public Health, Ein Kerem, Jerusalem, 91120, Israel
| | - R Calderon
- Unit of Epidemiology, The Hebrew University-Hadassah School of Public Health, Ein Kerem, Jerusalem, 91120, Israel
| | - Y Friedlander
- Unit of Epidemiology, The Hebrew University-Hadassah School of Public Health, Ein Kerem, Jerusalem, 91120, Israel
| | - O Paltiel
- Unit of Epidemiology, The Hebrew University-Hadassah School of Public Health, Ein Kerem, Jerusalem, 91120, Israel
| | - S Harlap
- Department of Psychiatry, School of Medicine, New York University, 550 1st Avenue, New York, NY 10017, USA
- Department of Epidemiology, Mailman School of Public Health, Columbia University, 722 West 168th Street, New York, NY 10032, USA
| |
Collapse
|
40
|
Steck SE, Gaudet MM, Britton JA, Teitelbaum SL, Terry MB, Neugut AI, Santella RM, Gammon MD. Interactions among GSTM1, GSTT1 and GSTP1 polymorphisms, cruciferous vegetable intake and breast cancer risk. Carcinogenesis 2007; 28:1954-9. [PMID: 17693660 DOI: 10.1093/carcin/bgm141] [Citation(s) in RCA: 41] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Isothiocyanates are anticarcinogenic phytochemicals found in cruciferous vegetables that both induce and are substrates for the gluthatione S-transferases (GSTs). The GSTs are phase II metabolizing enzymes involved in metabolism of various bioactive compounds. Functional polymorphisms in GST genes have been identified and may interact with cruciferous vegetable intake to affect cancer risk. We examined this hypothesis using data from the Long Island Breast Cancer Study Project, a population-based case-control study conducted in Long Island, NY, from 1996 to 1997. Cruciferous vegetable intake in the previous year was assessed via modified Block food frequency questionnaire. DNA was extracted from blood samples (n = 1052 cases and n = 1098 controls) and genotyped for GSTM1 deletion, GSTT1 deletion and GSTP1 Ile105Val using multiplex polymerase chain reaction and Taqman assays. Unconditional logistic regression was used to estimate adjusted odds ratios (ORs) and 95% confidence intervals (CI). We found an 86% increase in the OR for breast cancer among carriers of the GSTM1 null, GSTT1 null and GSTP 105Ile/Ile genotypes (OR = 1.86, 95% CI = 1.12, 3.08) and a 36% decrease in the OR among carriers of GSTM1 present, GSTT1 null and GSTP1 105Ile/Val + Val/Val genotypes (OR = 0.64, 95% CI = 0.42, 0.97) compared with GSTM1 present, GSTT1 present and GSTP1 105Ile/Ile carriers. We found no joint effects among GST polymorphisms and cruciferous vegetable intake and breast cancer risk. In conclusion, we found associations between specific combinations of three GST gene polymorphisms and breast cancer risk but these did not modify the association between cruciferous vegetable intake and breast cancer. Additional studies are needed to confirm the associations observed.
Collapse
Affiliation(s)
- S E Steck
- Department of Nutrition, University of North Carolina, Chapel Hill, NC, 27599 USA.
| | | | | | | | | | | | | | | |
Collapse
|
41
|
Perrin MC, Terry MB, Kleinhaus K, Deutsch L, Yanetz R, Tiram E, Calderon-Margalit R, Friedlander Y, Paltiel O, Harlap S. Gestational diabetes and the risk of breast cancer among women in the Jerusalem Perinatal Study. Breast Cancer Res Treat 2007; 108:129-35. [PMID: 17476589 DOI: 10.1007/s10549-007-9585-9] [Citation(s) in RCA: 31] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/09/2007] [Accepted: 03/26/2007] [Indexed: 10/23/2022]
Abstract
Gestational diabetes is becoming increasingly common; it is important to determine how it relates to future risk of disease. We investigated the relation of gestational diabetes to breast cancer in 37,926 women who had one or more live births in 1964-1976 for whom information had been collected on complications of pregnancy. In this cohort there were 1,626 cases of breast cancer reported to the Israel Cancer Registry before January 1, 2005 and 410 cases of gestational diabetes recorded from birth records. There were 29 cases of breast cancer among women diagnosed with gestational diabetes. Using Cox proportional hazards models to control for age and birth order at the first observed birth and other characteristics, we found that the incidence of breast cancer was increased among women diagnosed with gestational diabetes (relative rate = 1.5, 95% confidence interval 1.0-2.1). This effect was seen only among women 50 years and older (relative rate 1.7, 95% confidence interval 1.1-2.5) but not among women <50 (relative rate = 1.0, 95% confidence interval 0.5-2.1). The findings suggest that gestational diabetes may be an important early marker of breast cancer risk among post-menopausal women, but these results need to be confirmed in future studies.
Collapse
Affiliation(s)
- M C Perrin
- Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY 10032, USA.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
42
|
Stephenson P, O'Connor D, Terry M. Light regulation of tetrapyrrole biosynthesis in Arabidopsis. Comp Biochem Physiol A Mol Integr Physiol 2007. [DOI: 10.1016/j.cbpa.2007.01.519] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
43
|
Perrin MC, Terry MB, Kleinhaus K, Deutsch L, Friedlander Y, Paltiel O, Harlap S. Gestational Diabetes as a Risk Factor for Pancreatic Cancer: The Jerusalem Perinatal Study Cohort. Am J Epidemiol 2006. [DOI: 10.1093/aje/163.suppl_11.s109-c] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
44
|
Harlap S, Tiram E, Paltiel O, Deutsch L, Yanetz R, Perrin MC, Kleinhaus K, Terry MB, Friedlander Y. Lack of Male Offspring as a Risk Factor for Prostate Cancer in the Jerusalem Cohort. Am J Epidemiol 2006. [DOI: 10.1093/aje/163.suppl_11.s112-b] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
45
|
Shantakumar S, Terry MB, Teitelbaum SL, Britton JA, Neugut AI, Gammon MD. Reproductive Factors and Breast Cancer Risk among Older Women. Am J Epidemiol 2006. [DOI: 10.1093/aje/163.suppl_11.s97-a] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
46
|
Zhang FF, Chow WH, Hou L, Lissowska J, Morabia A, Terry MB. Genetic Polymorphisms in Folate Metabolism and Stomach Cancer Risk: A Comparison Between Conventional and Hierarchical Modeling Approaches. Am J Epidemiol 2006. [DOI: 10.1093/aje/163.suppl_11.s226-d] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
47
|
B Terry M, James TM, Trentham-Dietz A, Buist DSM. Nsaids and Mammographic Density. Am J Epidemiol 2006. [DOI: 10.1093/aje/163.suppl_11.s102-a] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
48
|
Terry MB, Titievsky L, Wei Y. 561: Rate of Growth in Early Life, Age at Menarche, and Adult Body Size. Am J Epidemiol 2005. [DOI: 10.1093/aje/161.supplement_1.s141] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
- M B Terry
- Columbia University, Mailman School of Public Health, New York, NY 10032
| | - L Titievsky
- Columbia University, Mailman School of Public Health, New York, NY 10032
| | - Y Wei
- Columbia University, Mailman School of Public Health, New York, NY 10032
| |
Collapse
|
49
|
Titievsky L, Terry MB, James T, Tehranifar P. 595-S: Effects of Childhood Socioeconomic Status on Adult Body Size in Women. Am J Epidemiol 2005. [DOI: 10.1093/aje/161.supplement_1.s149b] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
- L Titievsky
- Mailman School of Public Health, Columbia University, NY, NY 10032
| | - M B Terry
- Mailman School of Public Health, Columbia University, NY, NY 10032
| | - T James
- Mailman School of Public Health, Columbia University, NY, NY 10032
| | - P Tehranifar
- Mailman School of Public Health, Columbia University, NY, NY 10032
| |
Collapse
|
50
|
James TM, Terry MB, Titievsky L, Tehranifar P. 197-S: Socioeconomic Status and Age at Menarche Among a Racially Diverse Population of New York Girls. Am J Epidemiol 2005. [DOI: 10.1093/aje/161.supplement_1.s50] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
- T M James
- Mailman School of Public Health, Columbia University, NY, NY
| | - M B Terry
- Mailman School of Public Health, Columbia University, NY, NY
| | - L Titievsky
- Mailman School of Public Health, Columbia University, NY, NY
| | - P Tehranifar
- Mailman School of Public Health, Columbia University, NY, NY
| |
Collapse
|